ANTICORPOS BIESPECÍFICOS ANTI-PSEUDOMONAS COM REGIÕES FC MODIFICADAS E MÉTODOS DE USO DOS MESMOS
Bispecific antibodies targeting PcrV and Psl with modified Fc regions effectively address the challenge of Pseudomonas aeruginosa infections by enhancing half-life and killing activity, improving treatment outcomes in bronchiectasis.
Patent Information
- Application Number
- BR112025024282
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-08
- Publication Date
- 2026-11-10
AI Technical Summary
There is a need for improved agents to combat Pseudomonas aeruginosa infections due to the bacterium's high innate resistance to antibiotics and the formation of antibiotic-resistant biofilms, which cause chronic infections and impair lung function in individuals with bronchiectasis.
Development of bispecific anti-Pseudomonas antibodies that target both PcrV protein and Psl exopolysaccharide with modified IgG Fc regions, featuring specific amino acid substitutions, enhancing half-life, reducing aggregation, and promoting opsonophagocytic killing activity.
The modified antibodies exhibit increased half-life, reduced aggregation, and improved opsonophagocytic killing of Pseudomonas aeruginosa, potentially reducing infections and stabilizing lung function in individuals with bronchiectasis.
Abstract
Description
1 / 106 Bispecific anti-pseudomonas antibodies with modified FC regions and methods of their use. CROSS-REFERENCE TO RELATED DEPOSIT REQUESTS
[001] This application claims the benefit of priority under U.S. Provisional Application No. 63 / 501,036, filed May 9, 2023, which is incorporated herein by reference in its entirety. REFERENCE TO THE LIST OF SEQUENCES SENT ELECTRONICALLY
[002] The contents of the electronically submitted sequence listing (Name: PSEUD-110-WO-PCT_Seqlisting_ST26.xml; Size: 58580 bytes; and Creation Date: April 23, 2024) are incorporated herein in their entirety for reference purposes. FIELD OF REVELATION
[003] This disclosure relates to bispecific Psl and PcrV anti-Pseudomonas antibodies. These antibodies can be used, for example, in the prevention and treatment of Pseudomonas infections. Advantageously, the bispecific Psl and PcrV anti-Pseudomonas antibodies exhibit reduced aggregation during manufacturing and have a clinically useful half-life. In addition, the disclosure provides useful compositions for these therapies. BACKGROUND TO THE REVELATION
[004] Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative opportunistic pathogen that causes acute and chronic infections in compromised individuals (Ma et al., Journal of Bacteriology 189(22):8353 to 8356 (2007)). This is due, in part, to the bacterium's high innate resistance to clinically used antibiotics and, in part, to the formation of highly antibiotic-resistant biofilms (Drenkard E., Microbes Infect 5:1213 to 1219 (2003); Hancoke & Speert, Drug Resist Petition 870250102008, dated 07 / 11 / 2025, page 10 / 142 2 / 106 Update 3:247 to 255 (2000)). P. aeruginosa is a common cause of hospital-acquired infections in the Western world.
[005] It is a frequent causative agent of bacteremia in burn victims and immunocompromised individuals (Lyczak et al., Microbes Infect 2:1051 to 1060 (2000)). It is also the most common cause of nosocomial gram-negative pneumonia (Craven et al., Semin Respir Infect 11:32 to 53 (1996)), especially in patients undergoing mechanical ventilation, and is the most prevalent pathogen in the lungs of individuals with cystic fibrosis (Pier et al., ASM News 6:339 to 347 (1998)).
[006] Furthermore, it is known that P. aeruginosa colonizes the airways in patients with non-cystic fibrosis bronchiectasis. Non-cystic fibrosis bronchiectasis is a chronic disease characterized by abnormal and permanent dilation of the bronchi, resulting in chronic cough, sputum production, and recurrent bacterial airway infections. Patients with bronchiectasis suffer from high morbidity due to frequent exacerbations that impair quality of life and facilitate antibiotic resistance, leading to reduced lung function.
[007] The Pseudomonas exopolysaccharide Psl is reported to be anchored to the surface of P. aeruginosa and is believed to be important for facilitating colonization of host tissues and for the establishment / maintenance of biofilm formation (Jackson, KD, et al., J Bacteriol 186, 4466 to 4475 (2004)). Its structure comprises a mannose-rich repeating pentasaccharide (Byrd, MS, et al., Mol Microbiol 73, 622 to 638 (2009)).
[008] PcrV is a component of the type III secretion system. PcrV appears to be an integral component of the translocation apparatus of the type III secretion system that mediates the application of type III secretory toxins to target eukaryotic cells (Sawa T., et al. Nat. Med. 5, 392-398 (1999)). Active and passive immunization against PcrV improved acute lung injury and mortality in mice infected with cytotoxic P. aeruginosa (Sawa et al. 2009). The main effect of immunization Petition 870250102008, dated 07 / 11 / 2025, page 11 / 142 The 3 / 106 effect against PcrV was due to the blockage of translocation of secretory toxins type III into eukaryotic cells.
[009] Due to the increase in multidrug resistance, there remains a need in the art for the development of improved agents to combat Pseudomonas. BRIEF SUMMARY
[010] Bispecific anti-Pseudomonas aeruginosa antibodies of PcrV protein and Psl exopolysaccharide comprising modifications in the Fc region that may result in increased half-life are provided here.
[011] In some aspects provided herein, the present disclosure relates to a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa, wherein the antibody comprises a modified IgG Fc region, wherein the modified IgG Fc region comprises amino acid substitutions at two or more of the positions 432 to 437, numbered according to the EU Kabat numbering index, relative to a wild-type IgG Fc region; wherein (i) positions 432 and 437 are each substituted for cysteine; (ii) position 433 is histidine or is replaced by arginine, proline, threonine, lysine, serine, alanine, methionine or asparagine; (iii) position 434 is asparagine or is replaced by arginine, tryptophan, histidine, phenylalanine, tyrosine, serine, methionine or threonine; (iv) position 435 is histidine; and (v) position 436 is tyrosine or phenylalanine or is replaced by leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine or threonine; and wherein the antibody has an increased half-life compared with the half-life of a corresponding antibody with the wild-type Fc region. Petition 870250102008, dated 07 / 11 / 2025, page 12 / 142 4 / 106
[012] In some respects, the modified IgG Fc region is a modified IgG1 Fc region. In some respects, the modified IgG Fc region is a modified human IgG Fc region (e.g., a modified human IgG1 Fc region).
[013] In some respects, the bispecific antibody exhibits less aggregation in solution than an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20. In some respects, the bispecific antibody exhibits less aggregation in a shake plate overgrowth screen than a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.
[014] In some respects, the bispecific antibody promotes the opsonophagocytic killing activity of P. aeruginosa, and optionally the bispecific antibody mediates similar in vitro opsonophagocytic killing activity of P. aeruginosa as an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.
[015] In some respects, the bispecific antibody may additionally comprise an amino acid insertion after position 437, and optionally the amino acid insertion is glutamic acid.
[016] In some respects, the binding affinity of the bispecific antibody for FcRn at pH 6.0 is greater than the binding affinity for FcRn of a corresponding antibody with the Fc region of wild-type human IgG1 at pH 6. In some respects, the binding affinity of the bispecific antibody for FcRn at pH 7.4 is greater than the binding affinity for FcRn of a corresponding antibody with the Fc region of wild-type human IgG1 at pH 7.4. In some respects provided herein, Petition 870250102008, dated 07 / 11 / 2025, p. 13 / 142 5 / 106 The modified human IgG1 Fc region exhibits increased pH dependence of binding affinity for FcRn compared to a corresponding antibody with the wild-type human IgG1 Fc region.
[017] In some respects, the modified human IgG1 Fc region has amino acid substitutions at three of the positions 432, 433, 434, 435, 436, and 437. In some respects, the modified human IgG1 Fc region has amino acid substitutions at four of the positions 432, 433, 434, 435, 436, and 437. In some respects, the modified human IgG1 Fc region has amino acid substitutions at five of the positions 432, 433, 434, 435, 436, and 437. In some respects, the modified human IgG1 Fc region has amino acid substitutions at six of the positions 432, 433, 434, 435, 436, and 437.
[018] In some respects, the modified human IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:44 and the amino acid sequence of SEQ ID NO:33.
[019] In some respects, the bispecific antibody is not a HexaBody.
[020] In some respects, the bispecific antibody competitively inhibits the binding to PcrV of an antibody comprising a variable heavy chain (VH) region comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain (VL) region comprising the amino acid sequence of SEQ ID NO:14.
[021] In some respects, the bispecific antibody binds to the same PcrV epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:13 and a VL comprising the amino acid sequence of SEQ ID NO:14.
[022] In some respects, the bispecific antibody comprises an antigen-binding domain that binds to PcrV proteins of Pseudomonas aeruginosa and comprises a VH-CDR1 comprising the amino acid sequence of SEQ Petition 870250102008, dated 07 / 11 / 2025, p. 14 / 142 6 / 106 ID NO:1, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:6.
[023] In some respects, the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa comprises a VH comprising the amino acid sequence of SEQ ID NO:13 and / or a VL comprising the amino acid sequence of SEQ ID NO:14.
[024] In some respects, the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa comprises a variable heavy chain region and a variable light chain region in separate polypeptides.
[025] In some respects, the bispecific antibody competitively inhibits the binding to Psl of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:16.
[026] In some respects, the bispecific antibody binds to the same Psl epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:16.
[027] In some aspects given herein, the antibody comprises an antigen-binding domain that binds to the Pseudomonas aeruginosa exopolysaccharide Psl and comprises a variable heavy chain region VH-CDR1 comprising the amino acid sequence of SEQ ID NO:7, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:8, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:9, a variable light chain region VL-CDR1 comprising the amino acid sequence of SEQ ID Petition 870250102008, dated 07 / 11 / 2025, p. 15 / 142 7 / 106 NO:10, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:11 and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:12.
[028] In some aspects provided herein, the antigen-binding domain that binds to the Pseudomonas aeruginosa Psl exopolysaccharide comprises a VH comprising the amino acid sequence of SEQ ID NO:15 and / or a VL comprising the amino acid sequence of SEQ ID NO:16.
[029] In some respects, the antigen-binding domain that binds to the Pseudomonas aeruginosa Psl exopolysaccharide comprises a VH and a VL in the same polypeptide. In some respects, the antigen-binding domain that binds to the Pseudomonas aeruginosa Psl exopolysaccharide comprises a linker between the VH and the VL, optionally, the linker comprises the amino acid sequence of SEQ ID NO:18.
[030] In some respects, the antigen-binding domain that binds to the Pseudomonas aeruginosa Psl exopolysaccharide comprises an scFv. In some respects, the scFv comprises a ligand, optionally, the ligand comprises the amino acid sequence of SEQ ID NO:18. In some respects, the scFv is in the VH-ligand-VL orientation. In some respects, the scFv comprises the amino acid sequence of SEQ ID NO:17. In some respects, the scFv is on the same polypeptide chain as the VH of the antigen-binding domain that binds to the PcrV protein of Peudomonas aeruginosa. In some respects, the scFv is C-terminal to the VH of the antigen-binding domain that binds to the PcrV protein of Peudomonas aeruginosa.
[031] In some respects, the bispecific antibody comprises (i) a heavy chain of the formula VH-CH1-H1-L1-S-L2-H2-CH2-CH3, wherein VH is a variable domain of the anti-Pseudomonas aeruginosa PcrV heavy chain; CH1 is a constant region domain of heavy chain 1; H1 is a first fragment of Petition 870250102008, dated 07 / 11 / 2025, page 16 / 142 8 / 106 heavy chain hinge region; L1 is a first ligand; S is an anti-Pseudomonas aeruginosa scFv molecule; L2 is a second ligand; H2 is a second heavy chain hinge region fragment; CH2 is a heavy chain constant region 2 domain; and CH3 is a heavy chain constant region 3 domain; and (ii) a light chain of formula VL-CL, wherein VL is an anti-Pseudomonas aeruginosa light chain variable domain, and CL is an antibody light chain kappa constant region or an antibody light chain lambda constant region.
[032] In some respects, CH1 comprises the amino acid sequence of SEQ ID NO:21. In some respects, H1 comprises the amino acid sequence of SEQ ID NO:22. In some respects, L1 comprises the amino acid sequence of SEQ ID NO:28. In some respects, L2 comprises the amino acid sequence of SEQ ID NO:28. In some respects, H2 comprises the amino acid sequence of SEQ ID NO:23. In some respects, CH2-CH3 comprises the amino acid sequence of SEQ ID NO:30. In some respects, CL is a constant kappa region of antibody light chain. In some respects, CL comprises the amino acid sequence of SEQ ID NO:24.
[033] In some respects, the bispecific antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:31 and / or a light chain comprising the amino acid sequence of SEQ ID NO:20.
[034] In some aspects provided herein, the present disclosure relates to an isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein. In some aspects, the isolated polynucleotide further comprises a nucleic acid molecule encoding the light chain of the bispecific antibody described herein.
[035] In some respects given herein, the present disclosure relates to a vector comprising (i) a nucleic acid molecule encoding the chain Petition 870250102008, dated 07 / 11 / 2025, p. 17 / 142 9 / 106 heavy chain of the bispecific antibody, or (ii) a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein and a nucleic acid molecule encoding the light chain of the bispecific antibody described herein. In some respects, the present disclosure relates to a pair of vectors, wherein the first vector of the vector pair comprises a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein, and the second vector of the vector pair comprises a nucleic acid molecule encoding the light chain of the bispecific antibody described herein.
[036] In some aspects provided herein, the present disclosure relates to a host cell comprising (i) an isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein, (ii) a vector comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein or a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein and a nucleic acid molecule encoding the light chain of the bispecific antibody described herein, or (iii) a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein and a nucleic acid molecule encoding the light chain of the bispecific antibody described herein.In some aspects provided herein, the present disclosure relates to a host cell comprising a pair of vectors, wherein the first vector of the vector pair comprises a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein and the second vector of the vector pair comprises a nucleic acid molecule encoding the light chain of the bispecific antibody described herein.
[037] In some aspects given herein, the present disclosure relates to a method of producing a bispecific antibody, wherein the method comprises culturing the host cell described herein and optionally isolating the Petition 870250102008, dated 07 / 11 / 2025, page 18 / 142 10 / 106 bispecific antibody. In some respects, the present disclosure relates to a bispecific antibody produced by the method described herein.
[038] In some aspects given herein, the present disclosure relates to a composition comprising the bispecific antibody described herein and a pharmaceutically acceptable carrier.
[039] In some aspects provided herein, the present disclosure relates to a method of treating or preventing a Pseudomonas infection in an individual in need thereof, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein to the individual. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in the treatment or prevention of a Pseudomonas infection in an individual in need thereof. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or the composition comprising the bispecific antibody described herein for use in the treatment or prevention of a Pseudomonas infection in an individual in need thereof.
[040] In some respects, the infection is a lung infection, a respiratory tract infection, pneumonia, bacteremia, a bone infection, a joint infection, a skin infection, a burn infection, a wound infection, or any combination thereof.
[041] In some aspects provided herein, the present disclosure relates to a method of treating bronchiectasis in an individual in need thereof, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein. In some aspects provided herein, the present disclosure relates to the use of the antibody Petition 870250102008, dated 07 / 11 / 2025, p. 19 / 142 11 / 106 bispecific antibody described herein or to the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in the treatment of bronchiectasis in an individual in need thereof. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or to the composition comprising the bispecific antibody described herein for use in the treatment of bronchiectasis in an individual in need thereof.
[042] In some aspects provided herein, the present disclosure relates to a method for improving pre-bronchodilator forced expiratory volume 1 (FEV1) in an individual with bronchiectasis, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in improving pre-bronchodilator forced expiratory volume 1 (FEV1) in an individual with bronchiectasis. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or the composition comprising the bispecific antibody described herein for use in improving pre-bronchodilator forced expiratory volume 1 (FEV1) in an individual with bronchiectasis.
[043] In some aspects provided herein, the present disclosure relates to a method of reducing the Pseudomonas aeruginosa load in an individual with bronchiectasis, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein to the individual. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in Petition 870250102008, dated 07 / 11 / 2025, page 20 / 142 12 / 106 Reduction of Pseudomonas aeruginosa load in an individual with bronchiectasis. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or to the composition comprising the bispecific antibody described herein for use in reducing the Pseudomonas aeruginosa load in an individual with bronchiectasis.
[044] In some aspects provided herein, the present disclosure relates to a method for reducing bronchiectasis exacerbations in an individual in need thereof, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein to the individual. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in reducing bronchiectasis exacerbations in an individual in need thereof. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or the composition comprising the bispecific antibody described herein for use in reducing bronchiectasis exacerbations in an individual in need thereof.
[045] In some aspects provided herein, the present disclosure relates to a method for reducing the need for intravenous antibiotics in an individual with bronchiectasis, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein to the individual. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in reducing the need for intravenous antibiotics in an individual with bronchiectasis. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or the composition comprising the Petition 870250102008, dated 07 / 11 / 2025, page 21 / 142 13 / 106 bispecific antibody described herein for use in reducing the need for intravenous antibiotics in an individual with bronchiectasis.
[046] In some aspects provided herein, the present disclosure relates to a method of stabilizing lung function in an individual with bronchiectasis, wherein the method comprises administering the bispecific antibody described herein or the composition comprising the bispecific antibody described herein to the individual. In some aspects provided herein, the present disclosure relates to the use of the bispecific antibody described herein or the composition comprising the bispecific antibody described herein in the preparation of a medicament for use in stabilizing lung function in an individual with bronchiectasis. In some aspects provided herein, the present disclosure relates to the bispecific antibody described herein or the composition comprising the bispecific antibody described herein for use in stabilizing lung function in an individual with bronchiectasis.
[047] In some respects, bronchiectasis is non-cystic fibrosis bronchiectasis.
[048] In some respects, the method or use or antibody for use or composition for use additionally comprises the administration of an antibiotic.
[049] In some respects, the individual is colonized by Pseudomonas aeruginosa, and optionally, the individual's respiratory tract is colonized by Pseudomonas aeruginosa. BRIEF DESCRIPTION OF THE DRAWINGS / FIGURES
[050] Figure 1A shows the opsonophagocytic killing (OPK) activity of AZD0292 and gremubamab (MEDI3902) in an opsonophagocytosis assay. The data demonstrate that AZD0292 exhibits opsonophagocytic killing activity similar to gremubamab. (See Example 1)
[051] Figure 1B shows the anticytotoxic killing activity of AZD0292 and gremubamab (MEDI3902) in an anticytotoxicity assay. The data demonstrate Petition 870250102008, dated 07 / 11 / 2025, page 22 / 142 14 / 106 that AZD0292 exhibits equivalent anticytotoxic activity as grembumab. (See Example 1)
[052] Figure 2 shows the opsonophagocytic activity of AZD0292, gremubamab (MEDI3902), afucosylated gremubamab (gremubamab-AFuc), gremubamab-AFuc which additionally comprises YTE half-life extension mutations in its Fc region (gremubamab-AFuc-YTE), and negative control IgG mAb. The data demonstrate that AZD0292, which comprises N3Y half-life extension mutations, is more active in an opsonophagocytic assay compared to a gremubamab derivative with YTE half-life extension.
[053] Figure 3 shows increased serum exposure of AZD0292 in mice compared with gremubamab after intravenous administration of 10 mg / kg (IV). The study was performed in human FcRn Tg32 transgenic mice (n = 4 per time point). (See Example 2)
[054] Figure 4A shows the opsonophagocytic killing activity of AZD0292 and gremubamab when exposed to temperature variations (4 °C and 45 °C) and light exposure, compared with control groups. No difference was observed between AZD0292 and gremubamab under these stress conditions. (See Example 3)
[055] Figure 4B shows the anticytotoxicity activity between AZD0292 and gremubamab when exposed to temperature variations (4 °C and 45 °C) and light exposure, compared to control groups. No difference was observed between AZD0292 and gremubamab under these stress conditions. (See Example 3)
[056] Figure 5A shows the percentage of monomer in the compositions AZD0292 (hatched bars) and MEDI3902 (empty bars). (See Example 4)
[057] Figure 5B shows the percentage of aggregates in compositions AZD0292 (hatched bars) and MEDI3902 (empty bars). (See Example 4) Petition 870250102008, dated 07 / 11 / 2025, page 23 / 142 15 / 106
[058] Figure 6 shows the aggregation percentage for AZD0292 and for MEDI3902 for each clone tested. (See Example 4) The Y-axis labeling AH and the X-axis labeling 1-12 indicate grid positions on a 96-well plate, with each position representing a different expression clone.
[059] Figure 7 shows a scatter plot matrix to evaluate the correlation between the percentage of high molecular weight species, the average concentration of the purified PhyTip Protein A sample, and the titer on the last day of the 96-well fed-batch plate bioreactor. (See Example 4)
[060] Figures 8A to 8B show the normality test results for aggregates of AZD0292 (Figure 8A) and MEDI3902 (Figure 8B) using Anderson-Darling and Shapiro-Wilk tests. (See Example 4)
[061] Figure 8C shows the results of the t-test comparing the average percentage of aggregation between clones expressing MEDI3902 and AZD0292. (See Example 4)
[062] Figures 9A to 9B show the percentage of aggregation (Figure 9A) and the title at the end of the culture (Figure 9B) and associated with each clone that expresses AZD0292 (hatched bars) and MEDI3902 (empty bars). The clones are plotted based on the percentage values of aggregation in ascending order from left to right. (See Example 4)
[063] Figure 10 shows the aggregate percentage over months of storage at 40 °C. Data points for MEDI3902 are shown as squares (□) and AZD0292 are shown as triangles (□). (See Example 4) DETAILED DESCRIPTION I. Definitions
[064] The headings here are not limitations of the various aspects of the disclosure, which can be obtained by reference to the descriptive report as a whole. Petition 870250102008, dated 07 / 11 / 2025, p. 24 / 142 16 / 106 Consequently, the terms defined immediately below are more fully defined by reference to the descriptive report in its entirety.
[065] It should be noted that the term an entity refers to one or more of these entities; for example, an antibody is understood as representing one or more antibodies. Thus, the terms a (or an), one or more, and at least one can be used interchangeably in the present invention.
[066] Furthermore, and / or, when used in the present invention, should be understood as a specific disclosure of each of the two specified features or components with or without the other. Thus, the term and / or, as used in a phrase such as A and / or B in the present invention, is intended to include A and B, A or B, A (alone) and B (alone). Similarly, the term and / or, as used in a phrase such as A, B and / or C, is intended to encompass each of the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[067] As used herein, the terms about and approximately, when used to modify a numerical value or a numerical range, indicate that deviations of up to 10% above and up to 10% below the value or range remain within the intended meaning of the quoted value or range and include the exact number that these terms modify. It is understood that whenever aspects are described herein using the language about or approximately a numerical value or range, analogous aspects are also provided that refer to the specific numerical value or range.
[068] It is understood that whenever aspects are described herein using the language comprising, analogous aspects described in terms of consisting of and / or consisting essentially of are also provided. In this disclosure, comprises, which comprises, containing and having and the like may mean includes, including and the like; consisting essentially of or consists of Petition 870250102008, dated 07 / 11 / 2025, page 25 / 142 17 / 106 essentially in are open, allowing the presence of more than what is cited, provided that the basic or innovative characteristics of what is cited are not altered by the presence of more than what is cited, but excludes aspects of the prior art.
[069] Units, prefixes and symbols are denoted in their form accepted by the International System of Units (SI - Systeme International de Unites). The number ranges include the numbers that define the range.
[070] Unless otherwise indicated, amino acid sequences are written from left to right in amino to carboxy orientation.
[071] Unless otherwise defined, the technical and scientific terms used in the present invention have the same meaning as commonly understood by one skilled in the art to whom this disclosure relates. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, 2000, Oxford University Press, provide one skilled in the art with a general dictionary of many of the terms used in this disclosure.
[072] As used herein, the terms antibody and immunoglobulin are used interchangeably and refer to an antibody molecule that specifically recognizes and binds to a target, such as a protein, a polypeptide, a peptide, a carbohydrate, a polynucleotide, a lipid, or combinations thereof (e.g., a glycoprotein), through at least one antigen recognition site within the variable region of the immunoglobulin molecule. The term antibody encompasses monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, bispecific antibodies, and any other immunoglobulin molecule, provided the antibodies exhibit the desired biological activity. An antibody may be of any of the five major types. Petition 870250102008, dated 07 / 11 / 2025, page 26 / 142 18 / 106 classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of their constant heavy chain domains called alpha, delta, epsilon, gamma, and mu, respectively. The different classes of antibodies have different and well-known subunit structures and three-dimensional configurations. For the structure and properties of the different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th Ed., Daniel P. Stites, Abba I. Terr, and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and chapter 6.
[073] The term antibody fragment refers to a portion of an antibody. An antibody antigen-binding fragment refers to a portion of an antibody that binds to an antigen. An antibody antigen-binding fragment may comprise the antigen-determining regions of an antibody (e.g., complementarity-determining regions (CDRs)). Examples of antibody antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, and single-chain antibodies. An antibody antigen-binding fragment may be monovalent or multivalent (e.g., bivalent). An antibody antigen-binding fragment may be monospecific or multispecific (e.g., bispecific).An antigen-binding fragment of an antibody can be derived from any animal species, such as rodents (e.g., mouse, rat, or hamster) and humans, or it can be produced artificially.
[074] An antigen-binding domain or antigen-binding region refers to a monovalent portion of an antibody that binds to an antigen. An antigen-binding domain may comprise the antigen-determining regions of an antibody (e.g., complementarity-determining regions (CDRs)). An antibody or an antigen-binding fragment Petition 870250102008, dated 07 / 11 / 2025, page 27 / 142 19 / 106 of the same (including monospecific and multispecific (e.g., bispecific) antibodies or antigen-binding fragments thereof) may comprise an antigen-binding domain.
[075] The term Fc region, sometimes called Fc or Fc domain, as used herein refers to the portion of an IgG molecule that correlates with a crystallizable fragment obtained by papain digestion of an IgG molecule. The Fc region consists of the C-terminal half of the two heavy chains of an IgG molecule that are linked by disulfide bonds. It has no antigen-binding activity, but contains the carbohydrate portion and binding sites for complement and Fc receptors, including the FcRn receptor (see below). The Fc region contains the entire second constant domain CH2 (residues 231 to 340 of human IgG1, according to the Kabat numbering system) and the third constant domain CH3 (residues 341 to 447). The amino acid residues of the constant and variable IgG domains referred to herein are numbered according to the EU numbering index of Kabat et al. (Sequences of Proteins of Immunological Interest, 5aed., NIH publication 1991 No. 91-3242, which is incorporated herein by reference in its entirety), and include corresponding residues in other constant IgG domains, as determined by sequence alignment.
[076] The terms Fc-hinge region, Fc hinge region, Fc-hinge domain, or Fc hinge domain, as used herein, are used interchangeably and refer to a region of an IgG molecule consisting of the Fc region (residues 231 to 447) and a hinge region (residues 216 to 230) extending from the amino-terminal of the Fc region.
[077] Antibody fragments including single-chain antibodies may comprise the variable region(s) alone or in combination with all or a portion of the following: hinge region, CH1, CH2 and CH3 domains. Petition 870250102008, dated 07 / 11 / 2025, page 28 / 142 20 / 106
[078] Also included are antigen-binding fragments which also comprise any combination of variable region(s) with a hinge region, CH1, CH2 and CH3 domains.
[079] Antibodies or antigen-binding fragments disclosed herein may be of any animal origin, including birds and mammals. Antibodies may be human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse or chicken antibodies.
[080] Light chains are classified as kappa or lambda (□,□). Each heavy chain class can be connected to a kappa or lambda light chain. In general, light and heavy chains are covalently linked to each other, and the tail portions of the two heavy chains are linked to each other by covalent disulfide bonds or non-covalent bonds when immunoglobulins are generated by hybridomas, B cells, or genetically modified host cells. In the heavy chain, amino acid sequences extend from an N-terminal at the forked ends of the Y configuration to the C-terminal at the bottom of each chain.
[081] The light and heavy chains are divided into regions of structural and functional homology. The terms constant and variable are used functionally. The term constant domain refers to the portion of an immunoglobulin molecule with a more conserved amino acid sequence compared to the other portion of the immunoglobulin, the variable domain, which contains the antigen-binding site. The constant domain of the heavy chain contains the CH1, CH2, and CH3 domains, and the constant domain of the light chain contains the CL domain. The variable domains of the light chain (VL) and heavy chain (VH) portions determine antigen recognition and specificity. On the other hand, the constant domains of the light chain (CL) and heavy chain (CH1, CH2, or CH3) confer important biological properties, such as secretion, transplacental mobility, and binding to the Fc receptor. Petition 870250102008, dated 07 / 11 / 2025, page 29 / 142 21 / 106 complement binding and related domains. By convention, the numbering of the constant region domains increases as they become more distal from the antigen-binding site or the amino-terminal end of the antibody. The N-terminal portion is a variable region, and the C-terminal portion is a constant region; the CH3 and CL domains comprise the carboxy terminal of the heavy and light chains, respectively.
[082] As indicated above, the variable region allows the binding molecule to selectively recognize and specifically bind to epitopes on antigens. That is, the VL domain and the VH domain, or subset of the complementarity-determining regions (CDRs), of a binding molecule, for example, an antibody, combine to form the variable region that defines a three-dimensional antigen-binding site. This quaternary binding molecule structure forms the antigen-binding site present at the end of each arm of the Y. More specifically, the antigen-binding site is defined by three CDRs in each of the VH and VL chains.
[083] In naturally occurring antibodies, the six complementarity-determining regions or CDRs present in each antigen-binding domain are short, non-contiguous amino acid sequences that are specifically positioned to form the antigen-binding domain when the antibody assumes its three-dimensional configuration in an aqueous environment. The remaining amino acids in the antigen-binding domains, called framework regions, show less intermolecular variability. The framework regions largely adopt a □-sheet conformation, and the CDRs form loops that connect and, in some cases, are part of the □-sheet structure. Thus, the framework regions act to form a scaffold that provides the correct orientation of the CDRs through non-covalent interchain interactions. The antigen-binding domain formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen.This complementary surface. Petition 870250102008, dated 07 / 11 / 2025, p. 30 / 142 22 / 106 promotes the non-covalent binding of the antibody to its cognate epitope. The amino acids comprising the CDRs and the structure regions, respectively, can be easily identified for any variable heavy or light chain region by one skilled in the art, since they have been precisely defined (see, Sequences of Proteins of Immunological Interest, Kabat, E., et al., US Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901 to 917 (1987), which are incorporated herein by reference in their entirety).
[084] The terms Kabat numbering, Kabat EU numbering index, and similar terms are recognized in the art and refer to a numbering system of amino acid residues in the variable regions of the heavy and light chains of an antibody or an antigen-binding fragment thereof. In certain respects, CDRs can be determined according to the Kabat numbering system (see, for example, Kabat EA & Wu TT (1971) Ann NY Acad Sci 190: 382 to 391 and Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, fifth edition, US Department of Health and Human Services, NIH Publication No. 91-3242).Using the Kabat numbering system, CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which may optionally include one or two additional amino acids following 35 (called 35A and 35B in the Kabat numbering scheme) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In some respects, the CDRs of the antibodies described herein were determined according to the Kabat numbering scheme.
[085] Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901 to 917 (1987)). The end of the CDR-H1 loop Petition 870250102008, dated 07 / 11 / 2025, page 31 / 142 Chothia 23 / 106, when numbered using the Kabat numbering convention, varies between H32 and H34 depending on the loop length (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B are present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The hypervariable regions of AbM represent a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software. AbM Chothia Kabat Strap L1 L24-L34 L24-L34 L24-L34 L2 L50-L56 L50-L56 L50-L56 L3 L89-L97 L89-L97 L89-L97 H1 H31-H35B H26-H35B (Kabat Numbering) H26-H32..34 H1 H31-H35 H26-H35 (Chothia Numbering) H26-H32 H2 H50-H65 H50-H58 H52-H56 H3 H95-H102 H95-H102 H95-H102
[086] Single-chain Fvs (scFv) molecules are known in the art and are described, for example, in US patent 5,892,019. The immunoglobulin or antibody molecules covered by this disclosure may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.
[087] A monoclonal antibody or antigen-binding fragment of the same refers to a homogeneous antibody or population of antigen-binding fragments involved in the highly specific recognition and binding of a single antigenic determinant or epitope. This is in contrast to polyclonal antibodies which typically include different antibodies directed against different antigenic determinants. The term monoclonal antibody or fragment Petition 870250102008, dated 07 / 11 / 2025, page 32 / 142 24 / 106 antigen-binding fragments thereof encompass intact and complete monoclonal antibodies, as well as antibody fragments (such as Fab, Fab', F(ab')2, Fv), single-chain mutants (scFv), fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site. Furthermore, a monoclonal antibody or antigen-binding fragment thereof refers to such antibodies and antigen-binding fragments thereof made in any number of ways, including, but not limited to, by hybridoma, phage selection, recombinant expression, and transgenic animals.
[088] As used herein, human antibodies include antibodies with the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from transgenic animals for one or more human immunoglobulins and that do not express endogenous immunoglobulins, as described below and, for example, in US Patent No. 5,939,598 by Kucherlapati et al.
[089] By specifically binding, it is generally understood that a binding molecule, for example, a bispecific antibody or a fragment, variant or derivative thereof, binds to an epitope through an antigen-binding domain and that the binding implies some complementarity between an antigen-binding domain and the epitope. A binding molecule, as provided herein, may contain one, two, three, four or more binding domains which may be the same or different and which may bind to the same epitope or to two or more different epitopes. According to this definition, a binding molecule is said to specifically bind to an epitope when it binds to that epitope, through its antigen-binding domain, more readily than it would bind to a random and unrelated epitope. The term specificity is used in the present invention to qualify the relative affinity with which a certain binding molecule binds to an Petition 870250102008, dated 07 / 11 / 2025, p. 33 / 142 25 / 106 a certain epitope. For example, binding molecule A may be considered to have a higher specificity for a given epitope than binding molecule B, or it may be said that binding molecule A binds to epitope C with a higher specificity than it has for the related epitope D.
[090] An antibody that binds to the same epitope as a reference antibody refers to an antibody that comes into contact with the same amino acid and / or sugar residues as the reference antibody. The ability of an antibody to bind to the same epitope as a reference antibody can be determined using peptide scavenging mutagenesis or high-throughput alanine scavenging mutagenesis.
[091] An antibody is said to competitively inhibit the binding of a reference antibody to a given epitope if it preferentially binds to that epitope or to an overlapping epitope, so that it blocks, to some degree, the binding of the reference antibody to the epitope. Competitive inhibition can be determined by any method known in the art, for example, competitive ELISA assays. An antibody can be said to competitively inhibit the binding of the reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.
[092] The term bispecific antibody, as used herein, refers to an antibody that has binding domains specific for two different antigens or epitopes within a single antibody molecule. It will be recognized that molecules other than the canonical antibody structure can be constructed with two binding specificities. It will further be recognized that antigen binding by bispecific antibodies can be simultaneous or sequential. Triomes and hybrid hybridomas are two examples of cell lines that can secrete bispecific antibodies. Bispecific antibodies can also be constructed Petition 870250102008, dated 07 / 11 / 2025, p. 34 / 142 26 / 106 by recombinant means. (Strohlein and Heiss, Future Oncol. 6:1387 to 1394 (2010); Mabry and Snavely, IDrugs. 13:543 to 549 (2010)).
[093] As used herein, the term MEDI3902 or gremubamab refers to a bispecific antibody with a heavy chain with the amino acid sequence SEQ ID NO:19 and a light chain with the amino acid sequence SEQ ID NO:20. MEDI3902 is also known as gremubamab.
[094] As used herein, the term AZD0292 refers to a bispecific antibody comprising a heavy chain with the amino acid sequence of SEQ ID NO:31 and a light chain with the amino acid sequence of SEQ ID NO:20.
[095] The term FcRn receptor or FcRn, as used herein, refers to an Fc receptor (n indicates neonatal) that is known to be involved in the transfer of maternal IgGs to a fetus via the human or primate placenta, or yolk sac (rabbits) and to a newborn from colostrum via the small intestine. FcRn is also known to be involved in maintaining constant levels of IgG in serum by binding IgG molecules and recycling them in the serum. The binding of FcRn to naturally occurring IgG1, IgG2, and IgG4 molecules is strictly pH-dependent, with optimal binding at pH 6. IgG3 has a known variation at position 435 (i.e., human IgG has R435 instead of H435 found in human IgG1, IgG2, and IgG4), which may result in reduced binding at pH 6. FcRn comprises a heterodimer of two polypeptides, whose molecular weights are approximately 50 kDa and 15 kDa, respectively.The extracellular domains of the 50 kD polypeptide are related to the class I α chains of the major histocompatibility complex (MHC), and the 15 kD polypeptide has been shown to be non-polymorphic β2-microglobulin (β2-m). In addition to the placenta and neonatal intestine, FcRn is also expressed in various tissues across species, as well as in several types of endothelial cell lines. Petition 870250102008, dated 07 / 11 / 2025, page 35 / 142 27 / 106 is also expressed in adult human vascular endothelium, muscular vasculature, and hepatic sinusoids, and it is suggested that endothelial cells may be largely responsible for maintaining serum IgG levels in humans and mice. FcRn receptors include, for example, human and murine FcRn proteins, as well as homologs thereof with FcRn activity.
[096] An FcRn-binding fragment of an IgG constant domain, as that term is used herein, refers to a fragment of an IgG constant domain that binds to the FcRn receptor. An FcRn-binding fragment of an IgG constant domain may include the Fc region or the Fc hinge region; thus, it may include portions of the heavy chain CH2-CH3 region or the hinge-CH2CH3 region that are involved in FcRn binding (see Roopenian et al., Nature Rev. Immunol. 7:715–725 (2007)).
[097] KD, as this term is used here (sometimes also called Kd, Kd or Kd) is the equilibrium dissociation constant, a binding interaction between two molecules, such as an IgG and an FcRn. KD can be calculated from observed rate constants for association (kon) and dissociation (koff), such that KD is equal to the ratio of koff / kon.
[098] The term in vivo half-life, as used herein, refers to the biological half-life of a specific type of IgG molecule or its fragments containing FcRn binding sites in the circulation of a given animal and is represented by the time required for half of the amount administered to the animal to be eliminated from the circulation and / or other tissues in the animal. When a clearance curve of a given IgG is constructed as a function of time, the curve is generally biphasic with a rapid α phase representing an equilibrium of injected IgG molecules between the intra- and extravascular space and which is, in part, determined by the size of the molecules, and a longer β phase representing the Petition 870250102008, dated 07 / 11 / 2025, p. 36 / 142 28 / 106 catabolism of IgG molecules in the intravascular space. The term in vivo half-life corresponds practically to the half-life of IgG molecules in the β phase.
[099] As used herein, the term manipulated antibody refers to an antibody in which the variable domain in the heavy and light chains or in both is altered by at least partial replacement of one or more CDRs of an antibody of known specificity and, if necessary, by partial replacement of the framework region and sequence alteration. Although the CDRs may be derived from an antibody of the same class or even subclass as the antibody from which the framework regions are derived, it is predicted that the CDRs will be derived from an antibody of a different class and preferably from an antibody of a different species. A manipulated antibody in which one or more donor CDRs of a non-human antibody of known specificity are grafted onto a human heavy or light chain framework region is referred to in the present invention as a humanized antibody.It may not be necessary to replace all CDRs with the complete CDRs of the donor variable region to transfer antigen-binding capability from one variable domain to another. Instead, it may only be necessary to transfer the residues that are needed to maintain the activity of the target binding site. Given the explanations set forth in, for example, US patents 5,585,089, 5,693,761, 5,693,762 and 6,180,370, it will be well within the competence of those skilled in the art, either by performing routine experimentation or by trial and error testing, to obtain a functional engineered or humanized antibody.
[0100] A polypeptide, antibody, polynucleotide, vector, cell, or composition that is isolated is a polypeptide, antibody, polynucleotide, vector, cell, or composition that is in a form not found in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cells, or compositions include those that have been purified to a degree where they are no longer in a form in which they are found in nature. In Petition 870250102008, dated 07 / 11 / 2025, page 37 / 142 29 / 106 In some respects, an antibody, a polynucleotide, a vector, a cell, or a composition that is isolated is substantially pure. As used herein, substantially pure refers to a material that is at least 50% pure (i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.
[0101] The terms polypeptide, peptide, or protein are used interchangeably in the present invention to refer to amino acid polymers of any length. The polymer may be linear or branched, may comprise modified amino acids, and may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included in the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, non-natural amino acids, etc.), as well as other modifications known in the art. It is understood that, as the polypeptides of this disclosure are antibody-based, in some respects the polypeptides may occur as single chains or linked chains.
[0102] Administration in combination with one or more additional therapeutic agents (e.g., an antibiotic) includes simultaneous (concomitant) or consecutive administration in any order.
[0103] Terms such as treat or treatment or to treat or alleviate or to alleviate refer to therapeutic measures that cure, slow, reduce symptoms and / or halt the progression of a diagnosed pathological condition or disorder. Thus, those who need treatment include those already diagnosed or suspected of having the disorder. Petition 870250102008, dated 07 / 11 / 2025, page 38 / 142 30 / 106
[0104] The term airway neutrophilia refers to an accumulation of neutrophils in the air space of the lungs.
[0105] The term sputum neutrophilia refers to the presence of neutrophils in an individual's sputum. In some respects, the neutrophils in the sputum of an individual who needs treatment, for example, an individual with bronchiectasis, are increased compared to the neutrophils in the sputum of healthy controls.
[0106] By subject or individual or animal or patient or mammal, is meant any individual, for example, a mammalian individual, for whom diagnosis, prognosis or therapy is desired. Mammalian individuals include humans, domestic animals, farm animals and zoo, sporting or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, bears and so forth. II. Bispecific anti-Pseudomonas antibodies with modified Fc regions
[0107] Bispecific antibodies are provided here that bind specifically to Pseudomonas aeruginosa Psl and PcrV and comprise modified Fc regions. As provided herein, it has been surprisingly found that modifications to the Fc regions of these bispecific antibodies can result in increased half-life, but also in decreased aggregation associated with manufacturing without diminishing potency against Pseudomonas aeruginosa.
[0108] Exemplary sequences that may be present in a bispecific antibody that binds specifically to Psl and PcrV of Pseudomonas aeruginosa are presented in Table 1, defined according to Kabat nomenclature / numbering. Table 1: Sequences of bispecific antibodies SEQ ID NO: Description Sequence 1 HCDR1 antiPcrV SYAMN Petition 870250102008, dated 07 / 11 / 2025, p. 39 / 142 31 / 106 SEQ ID NO: Descrição Sequência 2 HCDR2 antiPcrV AITMSGITAYYTDDVKG 3 HCDR3 antiPcrV EEFLPGTHYYYGMDV 4 LCDR1 antiPcrV RASQGIRNDLG 5 LCDR2 antiPcrV SASTLQS 6 LCDR3 antiPcrV LQDYNYPWT 7 HCDR1 antiPsl PYYWT 8 HCDR2 antiPsl YIHSSGYTDYNPSLKS 9 HCDR3 antiPsl ADWDRLRALDI 10 LCDR1 anti-Psl RASQSIRSHLN 11 LCDR2 anti-Psl GASNLQS 12 LCDR3 anti-Psl QQSTGAWNW 13 VH anti-PcrV EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAP GKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS 14 VL anti-PcrV AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKA PKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CLQDYNYPWTFGQGTKVEIK 15 VH anti-Psl QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGK CLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAA DTAVYYCARADWDRLRALDIWGQGTMVTVSS 16 VL anti-Psl DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKA PKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQSTGAWNWFGCGTKVEIK 17 scFv anti-PcrV QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGK CLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSSGGGGSGGGGS GGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCRASQSIRSHL NWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSTGAWNWFGCGTKVEIK Petition 870250102008, dated 07 / 11 / 2025, page 40 / 142 32 / 106 SEQ ID NO: Description Sequence 18 Anti-Psl scFv ligand GGGGSGGGSGGGSGGGSGGGS 19 MEDI3902 heavy chain EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYANMNWVRQAP GKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP SNTKVDKRVEPKSCGGGGSGGGSQVQLQESGPGLVKPSET LSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNP SLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLR ALDIWGQGTMVTVSSGGGGGSGGGGGSGGGGSGGGGSDIQLT QSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIY GASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQST GAWNWFGCGTKVEIKGGGGSGGGSSDKTHTCPPCPAPELLG GPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAGGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 20 Cadeia leve de MEDI3902 e de AZD0292 AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKA PKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 21 CH1 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH KPSNTKVDKRV 22 H1 EPKSC 23 H2 DKTHTCPPCP 24 CL RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC 25 MEDI3902 CH2-CH3 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK 26 Ligand [GGGGS]n, where n is 0, 1,2, 3, 4, or 5 27 Ligand [GGGG]n, where n is 0, 1,2, 3, 4, or 5 Petition 870250102008, dated 07 / 11 / 2025, page 41 / 142 33 / 106 SEQ ID NO: Description Sequência 28 L1 [GGGGS]n, em que n é 2 29 L2 [GGGGS]n, em que n é 4 30 CH2-CH3 (N3Y) APELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEACSYHLCQKSLSLSP GK 31 Cadeia pesada de AZD0292 EVQLLESSGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAP GKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYCAKEEFLPGTHYYYGMDVWGQGTTVVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTGSVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP SNTKVDKRVEPKSCGGGGSGGGGSQVQLQESGPGLVKPSET LSLTCTVSGGISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNP SLKSRVTISGDTSKKQFSLKLSVTAADTAVYYCARADWDRLR ALDIWGQGTMVTVSSGGGGGSGGGSGGGGSDIQLT QSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIY GASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQST GAWNWFGCGTKVEIKGGGGSGGGGSDKTHTCPPCPAPELLG GPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCPKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEACSYHLCQKSLSLSPGK 32 Wild-type Fc subsequence MHEALHNHYTQKSLSLS 33 N3Y-containing Fc subsequence MHEACSYHLCQKSLSLS 34 IgG1, IgG2, and IgG4 His435 loop LHNHYT 35 IgG3 His435 loop LHNRFT 36 Loop region variant CXRHXC Petition 870250102008, dated 07 / 11 / 2025, p. 42 / 142 34 / 106 SEQ ID NO: Description Modified His435 sequence 37 Modified His435 loop region variant CRRHXC 38 Modified His435 loop region variant CXRHRC 39 Modified His435 loop region CSWHLC 40 Modified His435 loop region CSWHLE 41 Modified His435 loop region variant CXXXXC, where each X indicates any amino acid 42 Modified His435 loop region variant CXXXXCE,where each X indicates any amino acid 43 YTE variant of gremubamabe EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYANMNWVRQAP GKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSSAS TKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPEVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP SNTKVDKRVEPKSCGGGGSGGGGSQVQLQESGPGLVKPSET LSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNP SLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLR ALDIWGQGTMVTVSSGGGGGSGGGGGSGGGGSGGGGSDIQLT QSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIY GASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQST GAWNWFGCGTKVEIKGGGGSGGGGSDKTHTCPPCPAPELLG GPSVFLFPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAGGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK, Petition 870250102008, de 07 / 11 / 2025, pág. 43 / 142 35 / 106 SEQ ID NO: Description Sequence 44 Modified His435 hairpin (N3Y) region CSYHLC 45 AZD0292 heavy chain cDNA tcagatctca ccgtccttga cacgaagctt actgagcaca caggacctgc agggccgcca ccatggctgctc gcctgctc tggtggccac agctacaggt gtacactccg aggtgcagct gttggagtct gggggaggct tggtacagcc tggggggtc ctgagactct cctgtgcagc ctctggattc acctttagca gctatgccat gaactgggtc cgccaggctc cagggaaggg gctc gcatactaca ccgacgacgt gaagggccgg ttcaccatct ccagagacaa ttccaagaac acgctatatc tgcaaatgaa cagcctgagg gccgaggaca cggccgtata ttactgtgcg aaggaagaat ttttacctgg aacgcactac tactacggta tggacgtctg gggccagcct acccccgc aagggcccat ccgtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc ctggaacctca ggcgctctga ccagcggcgt gcacaccttc ccggccct tcctc gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatctttgtggcggagggg gctctggcgg agggggatcc caggtgcagc tgcaggaatc tggccctggc ctcgtgaagc cctccgagac actgtctctg acctgcaccg tgtccggcgg ctccatctcc ccttactact ggacctggat cagacagccc cctggcaagt gcctggaact gatcggctac atccactcct ccggctacac cgactacaac cccagcctga agtccagagt gaccatctcc ggcgacacct ccaagaagca gttctccctg aagctgtcct ccgtgaccgc cgctgatacc gccgtgtact actgcgccag agccgactgg gacagactga gagccctgga catctggggc cagggcacaa tggtcaccgt gtctagcgga ggcggaggat ctggtggtgg tggatctggc ggcggaggaa gtggtggcgg aggctctgat atccagctga cccagtcccc ctccagcctg tctgcttctg tgggcgaccg cgtgaccatc acctgtagag cctcccagtc catccggtcc cacctgaact ggtatcagca gaagcccggc aaggccccca agctgctgat ctacggcgcc tccaatctgc agtccggcgt gccctctaga ttctccggat ctggctccgg caccgacttt accctgacca tcagctccct gcagcccgag gacttcgcca cctactactg ccagcagtct accggcgcct ggaattggtt cggctgcggc accaaggtgg aaatcaaggg cggaggtggc tctggcggag ggggatccga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctgaggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tctacaccct gcccccatcc cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg Petition 870250102008, dated 07 / 11 / 2025, page 44 / 142 36 / 106 SEQ ID NO: Descrição Sequence cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttccctata gcaagctcac cgtggacaag agcaggtggc agcaggggagcctcctctc tgcatgcgc ttgctcatat cacctctgcc agaagagctt aagcctgtct ccgggtaaat gagcggccgc gaattcacgt gccagccatc tgttgtttgc ccccccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct ttcctaataa aatgaggaaa ttgcatcctctgtcgtcgtcgtc gggtggggtg gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgatca attt 46 Cadeia leve de AZD0292 cDNA tcagatctca ccgtccttga cacgaagcta ttcgaactac agttactgag cacacaggac ctcgtaccgc catccctcagcgcgcgc gcctgctgct gctgtggctg cccggggcca agtgcgctat tcagatgacc cagtccccct ccagcctgtc cgcctctgtg ggcgacagag tgaccatcac ctgtcgggcc tcccagggca tcagaaacga cctgggctgg tatcagcaga agccccggcag cctcgcgc caccctgcag tccggcgtgc cctccagatt ttccggctct ggctctggca ccgactttac cctgaccatc agctccctgc agcccgagga cttcgccacctactactgtc tgcaagacta caactacccc tggaccttcg gccagggcac caaggtggaa atcaagcgga ccgtggccgc tccctccgtg ttcatcttcc caccctccga cgagcagctg aagtccggca ccgcctccgt ggtctgcctg ctgaacaaccct gctcgc aggtggacaa cgccctgcag tccggcaact cccaggaatc cgtcaccgag caggactcca aggacagcac ctactccctg tccagcaccc tgaccctgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgaa gtgacccacc agggcctgtc cagccgtc accaggcct cgagtgctga tgaacgtgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagcagcagc a. Antigen-binding domains of anti-Pseudomonas bispecific antibodies with modified Fc regions
[0109] Bispecific antibodies that bind specifically to the Pseudomonas aeruginosa exopolysaccharide Psl (Psl) and to secretion protein type 3, PcrV, are provided here. Consequently, in some respects, the bispecific antibodies comprise a Psl-binding domain and a PcrV-binding domain.
[0110] A bispecific antibody provided herein may comprise an antigen-binding domain that binds specifically to P. aeruginosa PcrV. Petition 870250102008, dated 07 / 11 / 2025, p. 45 / 142 37 / 106 and competitively inhibits the binding to PcrV of an antibody comprising a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:14. In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa PcrV and binds to the same PcrV epitope as an antibody comprising a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:14.
[0111] In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to PcrV of P. aeruginosa and comprises (i) a heavy chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 sequences in SEQ ID NO:13 (e.g., Kabat-defined, AbM-defined or Chothia-defined CDRs) and (ii) a light chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 sequences in SEQ ID NO:14 (e.g., Kabat-defined, AbM-defined or Chothia-defined CDRs).
[0112] In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to PcrV of P. aeruginosa and comprises a CDR1 heavy chain comprising the amino acid sequence of SEQ ID NO:1, a CDR2 heavy chain comprising the amino acid sequence of SEQ ID NO:2, a CDR3 heavy chain comprising the amino acid sequence of SEQ ID NO:3, a CDR1 light chain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 light chain comprising the amino acid sequence of SEQ ID NO:5 Petition 870250102008, dated 07 / 11 / 2025, pp. 46 / 142 38 / 106 and a CDR3 light chain comprising the amino acid sequence of SEQ ID NO:6. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to PcrV of P. aeruginosa and comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:13. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to PcrV of P. aeruginosa and comprises a variable light chain region comprising the amino acid sequence of SEQ ID NO:14. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to PcrV of P. aeruginosa and comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:14.
[0113] In some respects, a bispecific antibody provided herein comprises a PcrV-binding domain with a variable heavy chain region and a variable light chain region in separate polypeptides.
[0114] In some respects, a bispecific antibody provided herein comprises a PcrV-binding domain with a variable heavy chain region and a variable light chain region in the same polypeptide. In some respects, the PcrV-binding domain comprises a Psl-binding domain with a variable heavy chain region and a variable light chain region in the same polypeptide and comprises a linker. The linker may be, for example, between the variable heavy chain region and the variable light chain region. The linker may be, for example, a glycine-rich linker or a glycine-serine linker. In some respects, the linker comprises the amino acid sequence of SEQ ID NO:18.
[0115] In some respects, a bispecific antibody provided herein comprises a PcrV-binding domain that is an scFv. In some respects, the Petition 870250102008, dated 07 / 11 / 2025, page 47 / 142 39 / 106 scFv binding to PcrV is in the VH-VL orientation, for example, VH-binding-VL. In some respects, the scFv binding to PcrV is in the VL-VH orientation, for example, VL-binding-VH.
[0116] In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to the Psl of P. aeruginosa and competitively inhibits the binding to the Psl of an antibody comprising a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:16. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to the Psl of P. aeruginosa and binds to the same Psl epitope as an antibody comprising a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:16.
[0117] In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa Psl and comprises (i) a heavy chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 sequences in SEQ ID NO:15 (e.g., Kabat-defined, AbM-defined or Chothia-defined CDRs) and (ii) a light chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 sequences in SEQ ID NO:16 (e.g., Kabat-defined, AbM-defined or Chothia-defined CDRs).
[0118] In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa Psl and comprises a heavy chain CDR1 comprising the Petition 870250102008, dated 07 / 11 / 2025, pp. 48 / 142 40 / 106 amino acid sequence of SEQ ID NO:7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:8, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:9, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:12. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa Psl and comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:15. In some aspects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa Psl and comprises a variable light chain region comprising the amino acid sequence of SEQ ID NO:16.In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to P. aeruginosa Psl and comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:16.
[0119] In some respects, a bispecific antibody provided herein comprises an antigen-binding domain that specifically binds to the Psl of P. aeruginosa and comprises a variable heavy chain region and a variable light chain region in the same polypeptide. In some respects, the PcrV-binding domain comprises a Psl-binding domain with a variable heavy chain region and a variable light chain region in the same polypeptide and comprises a linker. The linker may be, for example, between the variable heavy chain region and the variable light chain region. The linker may be, for example, Petition 870250102008, dated 07 / 11 / 2025, page 49 / 142 41 / 106 a glycine-rich ligand or a glycine-serine ligand. In some respects, the ligand comprises the amino acid sequence of SEQ ID NO:18.
[0120] In some respects, the bispecific antibody comprises a Psl-binding domain that is an scFv. The scFv may comprise a ligand. The ligand may be, for example, a glycine-rich ligand or a glycine-serine ligand. In some respects, the ligand comprises the amino acid sequence of SEQ ID NO:18. In some respects, the scFv is in the VH-VL orientation, for example, VH-ligand-VL. In some respects, the scFv is in the VL-VH orientation, for example, VL-ligand-VH. In some respects, the scFv comprises the amino acid sequence of SEQ ID NO:17.
[0121] In some respects, a bispecific antibody provided herein comprises a Psl-binding domain with a variable heavy chain region and a variable light chain region in separate polypeptides. b. Structure of bispecific anti-Pseudomonas antibodies with modified Fc regions
[0122] In some respects, a bispecific antibody provided here is an IgG antibody. The IgG antibody may be, for example, an IgG1 antibody. In some respects, an IgG1 antibody is a human IgG1 antibody. In some respects, an IgG1 antibody is a humanized IgG1 antibody.
[0123] The IgG antibody can be, for example, an IgG2 antibody. In some respects, an IgG2 antibody is a human IgG2 antibody. In some respects, an IgG2 antibody is a humanized IgG1 antibody.
[0124] The IgG antibody can be, for example, an IgG3 antibody. In some respects, an IgG3 antibody is a human IgG3 antibody. In some respects, an IgG3 antibody is a humanized IgG3 antibody. Petition 870250102008, dated 07 / 11 / 2025, page 50 / 142 42 / 106
[0125] The IgG antibody can be, for example, an IgG4 antibody. In some respects, an IgG4 antibody is a human IgG4 antibody. In some respects, an IgG4 antibody is a humanized IgG4 antibody.
[0126] In some respects, a bispecific antibody, as disclosed herein, has the structure of BS1, BS2, BS3 or BS4, all as shown in Figure 17 of document no. WO 2013 / 070615, which is incorporated herein by reference in its entirety.
[0127] In some respects, a bispecific antibody, as disclosed herein, has the BS4 structure, disclosed in detail in document no. WO 2013 / 070615, which is incorporated herein by reference in its entirety. For example, this disclosure provides a bispecific antibody in which an anti-Psl scFv molecule is inserted into the hinge region of each heavy chain of an anti-PcrV antibody or a fragment thereof.
[0128] In some respects, a bispecific antibody provided herein comprises (i) a heavy chain of the formula VH-CH1-H1-L1-S-L2-H2-CH2-CH3, wherein VH is a variable domain of the anti-PcrV heavy chain of P. aeruginosa; CH1 is a constant region domain of heavy chain 1; H1 is a first fragment of the heavy chain hinge region; L1 is a first ligand; S is an anti-Psl ScFv molecule of P. aeruginosa; L2 is a second ligand; H2 is a second fragment of the heavy chain hinge region; CH2 is a constant region domain of heavy chain 2; and CH3 is a constant region domain of heavy chain 3; and (ii) a light chain of the formula VL-CL, wherein VL is a variable domain of the anti-PcrV light chain of P. aeruginosa, and CL is either a constant kappa region of an antibody light chain or a lambda region of an antibody light chain. In some respects, CL is a constant kappa region of an antibody light chain.In some respects, VH comprises the amino acid sequence with SEQ ID NO:13, and VL comprises the amino acid sequence with SEQ ID NO:14. In some respects. Petition 870250102008, dated 07 / 11 / 2025, p. 51 / 142 43 / 106 aspects, scFv comprises the amino acid sequence of SEQ ID NO:15 and the amino acid sequence of SEQ ID NO:16. In some aspects, VH comprises the amino acid sequence of SEQ ID NO:13, VL comprises the amino acid sequence of SEQ ID NO:14, scFv comprises the amino acid sequence of SEQ ID NO:15 and the amino acid sequence of SEQ ID NO:16. In some aspects, scFv comprises the amino acid sequence of SEQ ID NO:17. In some aspects, VH comprises the amino acid sequence of SEQ ID NO:13, VL comprises the amino acid sequence of SEQ ID NO:14, scFv comprises the amino acid sequence of SEQ ID NO:17. In some aspects, CH1 comprises the amino acid sequence of SEQ ID NO:21. In some respects, L1 and L2 may be the same or different and may independently comprise (a) [GGGGS]n, where n is 0, 1, 2, 3, 4 or 5 (SEQ ID NO: 26), (b) [GGGG]n, where n is 0, 1, 2, 3, 4 or 5 (SEQ ID NO: 27) or a combination of (a) and (b).In some respects, H1 comprises the amino acid sequence EPKSC (SEQ ID NO: 22). In some respects, L1 comprises [GGGGS]n, where n is 2 (SEQ ID NO: 28). In some respects, L2 comprises [GGGGS]n, where n is 2 (SEQ ID NO: 28). In some respects, H2 comprises the amino acid sequence DKTHTCPPCP (SEQ ID NO: 23). In some respects, CH2-CH3 comprises the amino acid sequence of SEQ ID NO: 30. In some respects, CL comprises the amino acid sequence of SEQ ID NO: 24.
[0129] In some respects, a bispecific antibody provided herein comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:31. In some respects, a bispecific antibody provided herein comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:20. In some respects, a bispecific antibody provided herein comprises a polypeptide comprising the amino acid sequence of SEQ ID NO:31 and a polypeptide comprising the amino acid sequence of SEQ ID NO:20. Petition 870250102008, dated 07 / 11 / 2025, page 52 / 142 44 / 106
[0130] In some respects, the bispecific antibodies provided herein may be a tandem single-chain Fv (sc) fragment containing two different scFv fragments covalently anchored to each other by a linker (e.g., a polypeptide linker). (Ren-Heidenreich et al. Cancer 100:1095 to 1103 (2004); Korn et al. J Gene Med 6:642 to 651 (2004)). In some respects, the linker may contain, or be wholly or partially, a constant region of heavy-chain polypeptide such as a CH1 domain. In some respects, the two antibody fragments may be covalently anchored to each other by means of a polyglycine-serine or polyserine-glycine linker as described, for example, in U.S. Patents Nos. 7,112,324 and 5,525,491, respectively. Methods for generating bispecific scFv antibodies in tandem are described, for example, in Maletz et al. Int J Cancer 93:409 to 416 (2001); and Honemann et al. Leukemia 18:636 to 644 (2004).Alternatively, antibodies may be linear antibodies, as described, for example, in Zapata et al. Protein Eng. 8:1057 to 1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CH1 -VH-CH1) that form a pair of antigen-binding regions.
[0131] The discovery also encompasses variant forms of bispecific antibodies such as tetravalent dual variable domain immunoglobulin (DVD-Ig) molecules described in Wu et al. (2007) Nat Biotechnol 25(11):1290 to 1297. DVD-Ig molecules are designed so that two different variable light chain (VL) domains from two different parental antibodies are linked directly in tandem or via a short linker by recombinant DNA techniques, followed by the constant light chain domain. For example, the DVD-Ig light chain polypeptide may contain in tandem: (a) the VL of a PcrV-binding domain; and (b) the VL of a Psl-binding domain. Similarly, the heavy chain comprises the two tandemly linked variable heavy chain (VH) domains, followed by the constant CH1 domain and the Fc region. Petition 870250102008, dated 07 / 11 / 2025, page 53 / 142 45 / 106 For example, the DVD-Ig heavy chain polypeptide may contain in tandem: (a) the VH of a PcrV-binding domain; and (b) the VH of a Psl-binding domain. In this case, the expression of the two chains in a cell results in a heterotetramer containing four antigen-binding sites, two that bind specifically to PcrV and two that bind specifically to Psl. Methods for generating DVD-Ig molecules from two parental antibodies are further described, for example, in PCT publication no. WO 2008 / 024188 and no. WO 2007 / 024715, each of which is incorporated herein by reference in its entirety.
[0132] In some respects, a bispecific antibody provided herein does not comprise a modification that enhances hexamer formation. In some respects, a bispecific antibody provided herein is not a HexaBody. In some respects, a bispecific antibody provided herein is not an IgG-HexaBody. HexaBody technology is discussed, for example, in de Jong RN, et al., PLoS Biol. January 6, 2016;14(1):e1002344. doi: 10.1371 / journal.pbio.1002344. PMID: 26736041; PMCID: PMC4703389, which is incorporated herein by reference in its entirety.
[0133] In some respects, a bispecific antibody provided herein does not comprise an E345R substitution. In some respects, a bispecific antibody provided herein does not comprise an E430G substitution. In some respects, a bispecific antibody provided herein does not comprise an S440Y substitution. In some respects, a bispecific antibody provided herein does not comprise an E345R, E430G or S440Y substitution. c. Modified Fc regions in bispecific anti-Pseudomonas antibodies
[0134] As provided herein, a bispecific antibody with a modified Fc region may have one or more altered properties compared with a corresponding antibody without the modified Fc region (e.g., with a region Petition 870250102008, dated 07 / 11 / 2025, page 54 / 142 46 / 106 (Wild-type Fc). A matching antibody to a reference antibody with a modified Fc region is an antibody that contains the same amino acid sequence as the reference sequence, except for the specified modifications in the Fc region. Thus, for example, for AZD0292, gremubamab (MEDI3902) is a matching antibody, since gremubamab contains the same amino acid sequence as AZD0292, except for the N3Y modification in the Fc region of AZD0292.
[0135] Bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies provided here can exploit FcRn-mediated recycling to achieve serum half-lives that may be similar to or different from those of endogenous IgG, depending on the desired properties.By further imparting enhanced pharmacokinetic properties to biological therapeutic and diagnostic agents, the present disclosure provides opportunities for more appropriate dosing, reduced frequency of administration, or improved clearance while maintaining efficacy.
[0136] The present disclosure provides bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region) (e.g., of a human IgG, e.g., a human IgG1), which have modifications of at least one or more amino acid residues in the CH3 domain. The modifications may include amino acid substitutions, insertions, deletions, or any combination thereof. It should be understood that all references to amino acid residues of the IgG constant and variable domains appearing herein are numbered according to the EU numbering index of Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed., NIH publication 1991 no. 91-3242, which is incorporated herein by reference in its entirety), and include Petition 870250102008, dated 07 / 11 / 2025, page 55 / 142 47 / 106 corresponding residues in other constant IgG domains, as determined by sequence alignment.
[0137] More specifically, the discovery provides bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region (e.g., of a human IgG, e.g., a human IgG1)), which have modifications of one or more of the amino acid residues 432, 433, 434, 435, 436 or 437 and / or which have a single amino acid insertion between amino acids 437 and 438, which insertion is referred to here as 437*, in the His435 loop region of the CH3 domain, whose amino acid substitutions and / or insertions alter (increase or decrease) the binding affinity of the IgG constant domain or its FcRn-binding fragment to FcRn at a specific pH (e.g., pH 6.0 or pH 7.4).These modifications, including insertions between residues 437 and 438, will generally be referred to as modifications in the His435 loop region, that is, in amino acid residues 432 to 437. In certain respects, these modifications may exclude residue 435, so that the modified IgG constant domain, or the FcRn-binding portion thereof (e.g., an Fc region or a hinge Fc region), contains His435 which is found in wild-type human IgG1, IgG2, and IgG4. In certain respects, for example, modification of the analogous His435 loop region in human IgG3 which in the wild-type molecule includes arginine at position (R435) instead of the histidine (H435) found in IgG1, IgG2, and IgG4 and, moreover, is a known allelic variation site, these modifications include the substitution of a non-histidine residue of wild-type 435 for a histidine, to produce H435.In one aspect, the modified IgG constant domain, or the FcRn binding portion thereof (e.g., an Fc region or a hinge Fc region), is a human or humanized IgG constant domain or portion thereof. Petition 870250102008, dated 07 / 11 / 2025, p. 56 / 142 48 / 106 of its FcRn binding, although it may be murine. The constant domain of human or humanized IgG may be a constant domain of an IgG1, IgG2, IgG3, or IgG4 domain, or any subtype thereof.
[0138] As provided herein, amino acid modifications in the His435 loop region of the CH3 domain of the human IgG Fc fragment can affect the binding affinity of the bispecific antibody to FcRn at one or more pHs. These modifications can result in a change in the pH dependence of the bispecific antibody binding to FcRn. In some respects, amino acid modifications in the His435 loop region can result in a higher binding affinity of the bispecific antibody to FcRn at pH 6, pH 7.4, or pH 6.0 and 7.4 than that exhibited by a corresponding antibody with a wild-type IgG constant domain. Additionally or alternatively, the modifications can affect the in vivo half-life of the molecule.
[0139] The His435 loop region includes amino acid residues 432, 433, 434, 435, 436, and 437. The wild-type amino acid sequence of the His435 loop region (residues 432 to 437) of the CH3 domain of the Fc fragment of human IgG1, IgG2, and IgG4 is Leu-His-Asn-His-Tyr-Thr (SEQ ID NO:34) and of human IgG3 is Leu-HisAsn-Arg-Phe-Thr (SEQ ID NO:35). In some respects, one or more amino acid modifications in an Fc region are made at or near one or more of residues 432, 433, 434, 435, 436, and 437, for example, in a constant domain of human IgG, or an FcRn-binding domain thereof (e.g., an Fc region or an Fc-hinge region), or analogous residues thereof, as determined by amino acid sequence alignment, in other IgGs. These mutations include amino acid substitutions, as well as deletions and insertions. An illustrative site for an amino acid insertion is between residues 437 and 438, the added position of which is referred to here as 437*. Petition 870250102008, dated 07 / 11 / 2025, p. 57 / 142 49 / 106
[0140] In one aspect of the modified IgG constant domain, or of the FcRn-binding fragment thereof (e.g., an Fc region or a hinge Fc region), residue 435 is retained as a histidine (His435) (as in wild-type human IgG1, IgG2, and IgG4) or mutated to a histidine (as in IgG3, which natively contains R435 and is therefore mutated to R435H), while at least one of residues 432, 433, 434, 436, or 437 is substituted and / or an insertion is made at position 437*. In one aspect, neither residue 435 (His435) nor residue 433 (His433) is mutated (except that, for human IgG3, residue 435 has the R435H mutation so that it is His435), while at least one of residues 432, 434, 436, or 437 is substituted and / or an insertion is made at position 437*. In another aspect, the FcRn-binding domain has a substitution at 1, 2, 3, 4, or all 5 residues 432, 433, 434, 436, 437 and / or has an insertion at position 437* in the His435 loop region.In another aspect, the FcRn-binding domain has a substitution at three or more of the positions 432, 433, 434, 435, 436, or 437. In another aspect, the FcRn-binding domain has a substitution at four or more of the positions 432, 433, 434, 435, 436, or 437.
[0141] In one aspect, at least one of the positions 432 and 437 is substituted for cysteine and residues 433, 434, 435 and 436 are each independently substituted or unsubstituted. In certain aspects, residues 432 and 437 are both substituted for cysteines and residues 433, 434, 435 and 436 are each independently substituted or unsubstituted.
[0142] In one aspect, at least one of positions 432 and 437 is replaced by an amino acid selected from the group consisting of glutamine, glutamic acid, aspartic acid, lysine, arginine, and histidine, and residues 433, 434, 435, and 436 are each independently substituted or unsubstituted. In certain aspects, both positions 432 and 437 are replaced by an amino acid independently selected from the group consisting of glutamine, glutamic acid, aspartic acid, lysine, arginine, and histidine. Petition 870250102008, dated 07 / 11 / 2025, p. 58 / 142 50 / 106 glutamic acid, aspartic acid, lysine, arginine and histidine, and residues 433, 434, 435 and 436 are each independently substituted or unsubstituted.
[0143] In one aspect, a modified IgG constant domain, or an FcRn-binding fragment thereof (e.g., an Fc region or a hinge Fc region), contains at least three mutations in the His435 loop region and has a histidine at position 435 (the histidine at position 435 may be a wild-type residue or a mutation). Any of several permutations of three or more mutations (not including a mutation at 435, if present) is covered by the disclosure, including, without limitation, mutations at the following sites: Positions: 432, 433 and any one of 434, 436, 437 and 437* Positions: 432, 434 and any of 436, 437 and 437* Positions: 432, 436 and any position between 437 and 437* Positions: 432, 437 and 437* Positions: 433, 434 and any of 436, 437 and 437* Positions: 433, 436 and any of the positions between 437 and 437* Positions: 433, 437 and 437* Positions: 434, 436 and any of the positions between 437 and 437* Positions: 434, 437 and 437* Positions: 436, 437 and 437* Positions: 432, 433, 434 and any one of 436, 437 and 437* Positions: 432, 433, 436 and any of the positions between 437 and 437* Positions: 432, 433, 437 and 437* Positions: 432, 434, 436 and any of the positions between 437 and 437* Positions: 432, 434, 437 and 437* Positions: 432, 436, 437 and 437* Positions: 433, 434, 436 and any of the positions between 437 and 437* Positions: 433, 434, 437 and 437* Petition 870250102008, dated 07 / 11 / 2025, page 59 / 142 51 / 106 Positions: 434, 436, 437 and 437* Positions: 432, 433, 434, 436 and any of the positions between 437 and 437* Positions: 432, 433, 434, 437 and 437* Positions: 432, 433, 436, 437 and 437* Positions: 432, 434, 436, 437 and 437* Positions: 433, 434, 436, 437 and 437* Positions: 432, 433, 434, 436, 437 and 437*
[0144] In some aspects, the modified IgG constant domain, or the FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region), contains a mutation in the His435 loop region at positions 432, 433, 434, 436, and 437, and has a histidine at position 435 (the histidine at position 435 may be a wild-type residue or a mutation). In one aspect, a modified IgG Fc region comprises the amino acid sequence of SEQ ID NO:44. In one aspect, a modified IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:44. In one aspect, a modified human IgG Fc region comprises the amino acid sequence of SEQ ID NO:44. In one aspect, a modified human IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:44. The amino acid sequence of SEQ ID NO:44 can be referred to as the N3Y modification, N3Y mutations, and the like.
[0145] In one aspect, a modified IgG Fc region comprises the amino acid sequence of SEQ ID NO:33. In one aspect, a modified IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:33. In one aspect, a modified human IgG Fc region comprises the amino acid sequence of SEQ ID NO:33. In one aspect, a modified human IgG1 Fc region comprises the amino acid sequence of SEQ ID NO:33.
[0146] In an aspect of the modified IgG constant domain, or of the FcRn binding fragment thereof (for example, an Fc region or a region Petition 870250102008, dated 07 / 11 / 2025, p. 60 / 142 52 / 106 hinge-Fc), the His435 loop region of the CH3 domain of the Fc fragment has the amino acid sequence CXXXXC (residues 432 to 437; SEQ ID NO:41) or CXXXXCE (residues 432 to 437* with 437* being an insertion; SEQ ID NO:42). In one aspect, His435 loop amino acid sequences exemplifying various IgG HB20 mutants can be generated from a CXXXXCE (SEQ ID NO:42).
[0147] Without adhering to theory, the two cysteine residues may exert a stabilizing effect in the loop region, possibly forming a cystine disulfide. The predicted distance between the two cysteines is about 6.7 Å, which is in the range (4.6 to 7 Å) compatible with the formation of a cystine. In certain respects based on the His435 CXXXXC loop motif (SEQ ID NO:41), amino acid modifications for a modified IgG constant domain, or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region), are substitutions at one or more of the positions 432 to 437, with both positions 432 and 437 being substituted by cysteine. Position 435 is histidine. Position 433 may be substituted by arginine, proline, threonine, lysine, serine, alanine, methionine, or asparagine; In one respect, position 433 is serine.Position 434 can be replaced by asparagine, tryptophan, histidine, phenylalanine, tyrosine, serine, methionine, or threonine; in one aspect, position 434 is tyrosine. Position 436 can be replaced by leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine, or threonine; in one aspect, position 436 is leucine. In some aspects, the mutated His435 loop region contains a glutamic acid insertion at position 437*.
[0148] In one aspect, positions 432 and 437 are cysteine; position 433 is arginine, proline, threonine, lysine, serine, alanine, methionine, asparagine, or histidine; position 434 is arginine, tryptophan, histidine, phenylalanine, tyrosine, serine, methionine, threonine, or asparagine; position 435 is histidine; and position 436 is leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine, threonine, tyrosine, or phenylalanine. Petition 870250102008, dated 07 / 11 / 2025, page 61 / 142 53 / 106 In one aspect, the His435 loop region is CXRHXC (SEQ ID NO:36), wherein position 433 is histidine or is substituted by arginine, proline, serine, or asparagine, and wherein position 436 is substituted by leucine, arginine, isoleucine, methionine, or serine. In one aspect, the His435 loop region is CRRHXC (SEQ ID NO:37), wherein position 436 is substituted by leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine, or threonine. In one aspect, the His435 loop region is CXRHRC (SEQ ID NO:38), wherein position 433 is arginine, proline, threonine, lysine, serine, alanine, methionine, or asparagine. In one aspect, the His435 loop region is CSWHLC (SEQ ID NO:39) or CSWHLE (SEQ ID NO:40). In some aspects, in either of these aspects, the mutated His435 loop region contains a glutamic acid insertion at position 437*.
[0149] Amino acid modifications can be made by any method known in the art, and many of these methods are well-known and routine to those skilled in the art. For example, but not as a limitation, amino acid substitutions, deletions, and insertions can be performed using any well-known PCR-based technique. Amino acid substitutions can be made by site-directed mutagenesis (see, for example, Zoller and Smith, Nucl. Acids Res. 10:6487-6500, 1982; Kunkel, Proc. Natl. Acad. Sci USA 82:488, 1985, which are incorporated herein by reference in their entirety). Mutants that result in increased affinity for FcRn and increased half-life in vivo can be readily screened using well-known and routine assays, such as those described herein.Amino acid substitutions can be introduced into one or more residues in the IgG constant domain or in its FcRn-binding fragment (e.g., an Fc region or an Fc-hinge region), and the mutated domains or constant fragments can be expressed on bacteriophage surfaces that are then screened for increased FcRn-binding affinity. Petition 870250102008, dated 07 / 11 / 2025, page 62 / 142 54 / 106
[0150] Once generated, a mutated IgG constant domain, or a fragment thereof (e.g., an Fc region or an Fc hinge region), can be used in the construction of a bispecific antibody (e.g., by fusion with the variable portions of a bispecific antibody of interest) or an Fc fusion molecule (e.g., by fusion / conjugation of a heterologous portion). A modified IgG or Fc fusion molecule of the development can be generated by methods well known to those skilled in the art. Briefly, these methods include, but are not limited to, combining a variable region with the desired specificity (e.g., a variable region isolated from a phage display or expression library or derived from a human or non-human antibody) with a modified IgG constant region, or an FcRn binding fragment thereof (e.g., an Fc region or an Fc hinge region) with an altered half-life, as provided herein.Alternatively, those skilled in the art may generate a modified IgG or Fc fusion molecule by replacing at least one amino acid residue in the Fc region of an antibody or an Fc fusion molecule.
[0151] In addition to affecting half-life, the amino acid modifications described herein may alter (i.e., increase or decrease) the bioavailability (e.g., transport to mucosal surfaces or other target tissues) of molecules, in particular, altering (i.e., increasing or decreasing) the transport (or concentration or half-life) of the molecule to mucosal surfaces (e.g., of the lungs) or other portions of a target tissue. In some respects, amino acid modifications alter (e.g., increase or decrease) the transport or concentration or half-life of the molecule to the lungs. In some respects, amino acid modifications alter (e.g., increase or decrease) the transport (or concentration or half-life) of the molecule to the heart, pancreas, liver, kidney, bladder, stomach, large or small intestine, respiratory tract, lymph nodes, nervous tissue (central nervous tissue and / or Petition 870250102008, dated 07 / 11 / 2025, p. 63 / 142 55 / 106 peripheral), the muscle, the epidermis, the bone, the cartilage, the joints, the blood vessels, the bone marrow, the prostate, the ovary, the uterus, the tumor or cancerous tissue, etc.
[0152] In some respects, amino acid modifications do not abolish or alter one or more other immune effector or receptor-binding functions of the constant domain, for example, but not limited to, complement fixation, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and / or binding to one or more Fc gamma receptors, such as FcyRI, FcyRII, and FcyRIII. Modified IgGs and other detection molecules can be evaluated for effector function using well-known and routine methods in the art.
[0153] In addition, the discovery provides modified IgGs well suited for various diagnostic and therapeutic purposes. The discovery provides modified IgGs exhibiting varying levels of pH dependence of their binding to FcRn. Different levels of pH dependence may result in or correlate with different pharmacokinetic properties which, in turn, produce modified IgGs that are more suitable for some purposes than for others.
[0154] For example, some of the modified IgGs described here exhibit high affinity binding to FcRn at pH 6.0, along with a high level of pH dependence in their FcRn binding and an observed increase in in vivo half-life. IgGs modified in this aspect of development have utility, for example, when employed as therapeutic agents in applications where a longer in vivo half-life is desirable. Optionally, the modified IgG also exhibits other enhanced pharmacokinetic properties, such as retained or increased ability to interact with Fc ligands, such as Fcy and C1q receptors, robust killing activity. Petition 870250102008, dated 07 / 11 / 2025, p. 64 / 142 56 / 106 opsonophagocytic (OPK) and the ability to mediate Fc effector functions (e.g., CDC, ADCC).
[0155] In contrast, some of the modified IgGs described here exhibit high-affinity binding to FcRn at pH 6.0, along with a lower level of pH dependence in their binding to FcRn (typically as a result of increased affinity for FcRn at pH 7.4) and an observed decrease in in vivo half-life. IgGs modified in this aspect of development are useful, for example, when employed as therapeutic agents in applications where a shorter in vivo half-life is desirable, such as in the treatment of certain autoimmune conditions. They may also be well-suited for diagnostic applications, such as when used as a biological imaging agent, where rapid clearance of body fluids or tissues is desired.
[0156] Furthermore, the discovery relates to amino acid modifications (e.g., substitutions, insertions, or deletions) in the constant domain of IgG, or in the FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region), which were found to increase the affinity of the constant domain of IgG, or the fragment thereof, for FcRn at pH 6, and which optionally alter the affinity of IgG or the fragment thereof for FcRn at pH 7.4, thus altering the pH dependence of the binding affinity of the constant domain of IgG, or the fragment thereof (e.g., an Fc region or an Fc-hinge region) for FcRn. Furthermore, these modifications can increase or decrease the in vivo half-life of the molecule.
[0157] In one aspect, the disclosure addresses the pharmaceutical importance of increasing the in vivo half-lives of bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies. To this end, the disclosure provides bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies containing a modified IgG constant domain or an FcRn-binding fragment thereof (by Petition 870250102008, dated 07 / 11 / 2025, p. 65 / 142 57 / 106 example, an Fc region or an Fc hinge region (e.g., of a human IgG, e.g., a human IgG1) that confers increased in vivo half-life in immunoglobulins and other bioactive molecules. In this respect, the present disclosure relates to bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies that have an increased in vivo half-life by virtue of the presence of a modified IgG constant domain, or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region (e.g., of a human IgG, e.g., a human IgG1)), wherein the IgG constant domain, or the fragment thereof, is modified (e.g., by amino acid substitution, deletion, or insertion) to alter (increase or decrease) the binding affinity of the IgG constant domain or the FcRn-binding fragment to FcRn at a specific pH (e.g., pH 6.0 or pH 7.4).In one aspect, the constant domain of IgG, or the FcRn-binding fragment thereof, is modified to increase the binding affinity for FcRn at pH 6.0 relative to the binding affinity for FcRn at pH 7.4. The in vivo half-lives of the modified IgGs of the development can be conveniently evaluated in a transgenic human mouse model or in a cynomolgus macaque primate model, as described, for example, in Example 2 below.
[0158] Most modified development antibodies, whether exhibiting increased or decreased in vivo half-lives compared to each other or to their unmodified or wild-type counterparts, contain an IgG constant domain, or an FcRn-binding fragment thereof, which exhibits greater FcRn-binding affinity at pH 6.0 than the wild-type IgG constant domain.
[0159] More generally, those skilled in the art will understand that the Fc variants of the revelation, whether they exhibit increased or decreased in vivo half-lives compared to each other or to their unmodified counterparts or Petition 870250102008, dated 07 / 11 / 2025, p. 66 / 142 58 / 106 of the wild type may have altered FcRn binding properties. Examples of binding properties include, but are not limited to, binding specificity, equilibrium dissociation constant (KD), dissociation and association rates (kon and koff, respectively), binding affinity, and / or avidity. It is well known in the art that the equilibrium dissociation constant (KD) is defined as koff / kon. It is understood that a higher affinity interaction will have a lower KD and, conversely, that a lower affinity interaction will have a higher KD. However, in some cases, the kon or koff value may be more relevant than the KD value.
[0160] Although the relationships between IgG binding affinity for FcRn, the pH dependence of this binding affinity, and the in vivo half-life are complex, for those constant IgG domains that exhibit high binding affinity for FcRn at pH 6.0 (e.g., KDs of less than about 500 nM), as the binding affinity for FcRn at pH 7.4 increases (generally reflecting the reduced pH dependence of FcRn binding), for example, if the KD at pH 7.4 falls below about 1 μM in the nanomolar range, the result may, in some cases, be a shorter in vivo half-life for modified IgG. Conversely, reduced binding affinity for FcRn at pH 7.4 (e.g., KDs at pH 7.4 above about 1 μM) coupled with high binding affinity at pH 6.0 (e.g., KDs less than about 500 nM), generally reflecting a greater pH dependence of FcRn binding, may in some cases result in a longer in vivo half-life.
[0161] In some respects, modified IgGs and other detection molecules contain a modified IgG constant domain or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region), which exhibits a KD for FcRn binding at pH 6.0 less than 100 nM, less than 200 nM, less than 300 nM, less than 400 nM, less than 500 nM, or less than 1000 nM. Modified detection IgGs may, for example, be characterized by KD values for FcRn binding at pH 6.0 of 10 nM to 500 nM, 50 nM to 500 Petition 870250102008, dated 07 / 11 / 2025, p. 67 / 142 59 / 106 nM. In some respects, the modified IgG of the revelation exhibits at least a 10-fold increase, at least a 20-fold increase, or at least a 50-fold increase in FcRn binding affinity at pH 6.0 compared to a wild-type IgG constant domain or FcRn binding fragment of the same.
[0162] Additionally or alternatively, a modified IgG may exhibit a binding affinity for FcRn at pH 7.4 that is between 10 nM and 50 μM. Without delving into theory, it can be observed that there may be a limit: at pH 7.4, a KD of about 1 μM or more (for example, a KD of 1 μM, 5 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM or more; that is, binding affinities in the micromolar or millimolar range showing lower binding affinity for FcRn) may be associated with a modified IgG or another molecule with a longer half-life (slower clearance), while a KD of less than 1 μM at pH 7.4 (for example, a KD of 50 nM, 100 nM, 200 nM, 500 nM, 800 nM up to about 1000 nM; that is, binding affinities in the nanomolar range), showing greater binding affinity for FcRn) may be associated with a modified IgG or another molecule with a shortened half-life (faster clearance).An increased half-life for modified IgG or another molecule is generally, but not always, associated with pH-dependent binding to FcRn characterized by a KD of 50 nM at 400 nM or 500 nM for binding at pH 6 and a KD of more than 1 μM at pH 7.4.
[0163] The structure of the IgG constant domain (or the FcRn-binding fragment thereof, for example, an Fc region or an Fc-hinge region) outside the His435 loop region may be referred to here as the IgG base structure or background of the molecule, and these two terms are used interchangeably. The revelation thus contemplates modified IgGs with mutations in the His435 loop region incorporated into a wild-type IgG base structure or a mutant IgG base structure. Any mutant IgG base structure may Petition 870250102008, dated 07 / 11 / 2025, page 68 / 142 60 / 106 to be used; basic structures of mutant IgG, exemplifying but not limited to, are described here. In certain aspects, the basic structure of IgG has a sequence according to SEQ ID NO:25 or 19.
[0164] Development-modified immunoglobulin molecules include IgG molecules that naturally contain an FcRn-binding domain, as well as other non-IgG immunoglobulins (e.g., IgE, IgM, IgD, IgA, and IgY) or immunoglobulin fragments that have been manipulated to contain an FcRn-binding fragment (i.e., fusion proteins comprising non-IgG immunoglobulin or a fragment thereof and an FcRn-binding domain, such as an Fc region or an Fc hinge region). In both cases, the FcRn-binding domain has one or more amino acid modifications that increase the affinity of the constant domain fragment for FcRn at pH 6.0 and optionally affect (increase or decrease) the pH dependence of the FcRn binding.
[0165] Modified immunoglobulins include any immunoglobulin molecule that binds (preferably immunospecifically, i.e., competes for nonspecific binding, as determined by immunoassays well known in the art for assessing specific antigen-antibody binding) to an antigen and contains an FcRn binding fragment. These antibodies include, but are not limited to, polyclonal, monoclonal, bispecific, multispecific, human, humanized, and chimeric antibodies, and single-chain antibodies.
[0166] Immunoglobulins (and other proteins used herein) may be of any animal origin, including birds and mammals. Antibodies may be, for example, human, rodent (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, human antibodies include antibodies with the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from transgenic animals for one or more Petition 870250102008, dated 07 / 11 / 2025, page 69 / 142 61 / 106 human immunoglobulins and those that do not express endogenous immunoglobulins, as described below and, for example, in US patent no. 5,939,598 by Kucherlapati et al. d. Additional properties of bispecific anti-Pseudomonas antibodies with modified Fc regions
[0167] In some respects, a bispecific antibody provided herein (e.g., AZD0292) mediates cytotoxic activity against Pseudomonas (e.g., Pseudomonas aeruginosa). In some respects, a bispecific antibody provided herein (e.g., AZD0292) directs Pseudomonas (e.g., Pseudomonas aeruginosa) to opsonophagocytic killing (OPK). Methods for assessing cytotoxic and / or OPK activity are known in the art and provided herein, for example, in Example 1.
[0168] In some respects, a bispecific antibody provided herein (e.g., AZD0292) has similar cytotoxic activity against Pseudomonas (e.g., Pseudomonas aeruginosa) as gremubamab (MEDI3902). In some respects, a bispecific antibody provided herein (e.g., AZD0292) has similar OPK activity against Pseudomonas (e.g., Pseudomonas aeruginosa) as gremubamab. In some respects, a bispecific antibody provided herein (e.g., AZD0292) has similar cytotoxic activity and OPK activity against Pseudomonas (e.g., Pseudomonas aeruginosa) as gremubamab.
[0169] In some respects, a bispecific antibody provided herein (e.g., AZD0292) prevents cell attachment, for example, it prevents the attachment of Pseudomonas (e.g., Pseudomonas aeruginosa) to host cells. Methods for assessing attachment prevention are known in the art and provided, for example, in document no. WO 2013 / 070615, which is incorporated herein by reference in its entirety. In some respects, a bispecific antibody provided herein (e.g., AZD0292) interrupts biofilm formation. In some Petition 870250102008, dated 07 / 11 / 2025, page 70 / 142 62 / 106 aspects, a bispecific antibody provided here (e.g., AZD0292) inhibits the formation of primary colonies.
[0170] In some respects, a bispecific antibody provided herein (e.g., AZD0292) exhibits less aggregation in solution than gremubamab. In some respects, a bispecific antibody provided herein (e.g., AZD0292) exhibits less aggregation in a shake plate overgrowth screening than gremubamab (see, for example, Example 4). III. Uses of bispecific anti-Pseudomonas antibodies with modified Fc regions
[0171] Methods of preparation and administration of Pseudomonas Psl and / or PcrV binding molecules are also provided herein, for example, an antibody or fragment, a variant or derivative thereof, as disclosed herein to an individual in need thereof. The route of administration of the anti-Pseudomonas Psl and / or PcrV binding molecules, for example, antibody or fragment, variant or derivative thereof, may be, for example, parenteral. The term parenteral, as used herein, includes, for example, intravenous, intra-arterial, intraperitoneal, intramuscular or subcutaneous administration. A suitable form of administration would be an injectable solution, in particular for intravenous or intra-arterial injection or drip.However, in other methods consistent with the teachings herein, an anti-Pseudomonas Psl and / or PcrV binding molecule, for example, an antibody or fragment, variant or derivative thereof, as disclosed herein, may be applied directly to the site of the adverse cell population, for example, infection, thereby increasing the exposure of the diseased tissue to the therapeutic agent. For example, an anti-Pseudomonas Psl and / or PcrV binding molecule may be administered directly to ocular tissue, burn injury or lung tissue. Petition 870250102008, dated 07 / 11 / 2025, page 71 / 142 63 / 106
[0172] Pseudomonas Psl and / or PcrV binding molecules, for example, antibodies or fragments, variants or derivatives thereof, as disclosed herein, can be administered in a pharmaceutically effective amount for the in vivo treatment of a Pseudomonas infection. In this regard, it will be recognized that the disclosed bispecific antibodies will be formulated in such a way as to facilitate administration and promote the stability of the active agent. For the purposes of this application, a pharmaceutically effective amount refers to an amount sufficient to achieve effective binding to a target and achieve a benefit, for example, to treat, improve, reduce, clear or prevent Pseudomonas infection.
[0173] Some aspects relate to a method of preventing or treating a Pseudomonas infection in an individual in need thereof, comprising administering to the individual an effective amount of the binding molecule or fragment thereof, of the antibody or fragment thereof. In other aspects, Pseudomonas infection is a P. aeruginosa infection. In some aspects, the individual is a human being. In certain aspects, the infection is an eye infection, a lung infection, a burn infection, a wound infection, a skin infection, a blood infection, a bone infection, or a combination of two or more of these so-called infections. In other aspects, the individual suffers from acute pneumonia, burn injury, corneal infection, cystic fibrosis, or a combination thereof.
[0174] Certain aspects relate to a method of blocking or preventing the attachment of P. aeruginosa to epithelial cells comprising placing a mixture of epithelial cells and P. aeruginosa in contact with the binding molecule or fragment thereof, the antibody or fragment thereof described herein.
[0175] A method for enhancing OPK of P. aeruginosa is also disclosed, comprising placing a mixture of phagocytic cells and P. Petition 870250102008, dated 07 / 11 / 2025, page 72 / 142 64 / 106 aeruginosa in contact with the binding molecule or fragment thereof, the antibody or fragment thereof, the composition, the polynucleotide, the vector or the host cell described herein. In other respects, phagocytic cells are differentiated HL-60 cells or human polymorphonuclear leukocytes (PMNs). a. Methods and uses of bispecific anti-Pseudomonas antibodies with modified Fc regions in the treatment of bronchiectasis
[0176] As demonstrated herein, bispecific antibodies that bind specifically to Pseudomonas aeruginosa Psl and PcrV and have modified Fc regions (e.g., AZD0292) are useful in the treatment of individuals with bronchiectasis. Consequently, treatment methods using these bispecific antibodies, uses of these bispecific antibodies in the preparation of medicines, and bispecific antibodies for use in treatments are provided herein.
[0177] In some respects, methods of treatment for bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) are provided herein. The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0178] In some respects, methods are provided here for improving pre-bronchodilator forced expiratory volume (FEVi) in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa. Petition 870250102008, dated 07 / 11 / 2025, page 73 / 142 65 / 106
[0179] In some respects, methods are provided here for reducing the Pseudomonas aeruginosa burden in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0180] In some respects, methods are provided here for reducing bronchiectasis exacerbations in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may, for example, reduce bronchiectasis exacerbations requiring hospitalization and / or reduce bronchiectasis exacerbations requiring antibiotics. The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0181] In some respects, methods are provided here for reducing the need for intravenous antibiotics in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0182] In some respects, methods are provided here for establishing pulmonary function in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may include administering to the individual Petition 870250102008, dated 07 / 11 / 2025, page 74 / 142 66 / 106 is a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual colonized by Pseudomonas aeruginosa.
[0183] In some respects, methods are provided here for improving the frequency and / or intensity of cough in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0184] In some respects, methods are provided here for reducing the symptoms of bronchiectasis in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0185] In some respects, methods are provided here for improving the quality of life in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0186] In some respects, methods are provided here for eradicating Pseudomonas aeruginosa in an individual with bronchiectasis (e.g., Petition 870250102008, dated 07 / 11 / 2025, page 75 / 142 67 / 106 non-cystic fibrosis bronchiectasis). The methods may involve administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0187] In some respects, methods are provided here for inducing sustained suppression of Pseudomonas aeruginosa in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0188] In some respects, methods are provided here for reducing the risk of progression of Pseudomonas aeruginosa-related bronchiectasis in an individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). The methods may comprise administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292). The individual may be, for example, an individual who is colonized by Pseudomonas aeruginosa.
[0189] Bronchiectasis suitable for treatment according to the methods and uses provided herein may be non-cystic fibrosis bronchiectasis. In some respects, non-cystic fibrosis bronchiectasis has been confirmed by computed tomography (CT) scan of the chest demonstrating bronchiectasis affecting 1 or more lobes in an individual. Petition 870250102008, dated 07 / 11 / 2025, page 76 / 142 68 / 106
[0190] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual who is colonized by Pseudomonas aeruginosa. Individuals with Pseudomonas aeruginosa colonization may be identified, for example, using routine sputum culture. In some respects, the individual is colonized with a strain of Pseudomonas aeruginosa comprising a genome that includes a Psl operon. In some respects, the individual is colonized with a strain of Pseudomonas aeruginosa comprising a genome that includes PcrV coding loci.
[0191] In some respects, the individual is chronically infected with Pseudomonas aeruginosa. As used herein, an individual who is chronically infected refers to an individual colonized by at least two isolates of Pseudomonas aeruginosa, simultaneously or sequentially, while clinically stable over the course of one year.
[0192] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual with airway neutrophilia and / or sputum neutrophilia.
[0193] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual with a history of at least two moderate to severe bronchiectasis exacerbations per year requiring antibiotics.
[0194] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual with a history of at least one exacerbation requiring hospital care. Petition 870250102008, dated 07 / 11 / 2025, page 77 / 142 69 / 106
[0195] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual taking long-term nebulized antibiotics.
[0196] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be an individual with chronic obstructive pulmonary disease (COPD).
[0197] An individual with bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) suitable for treatment according to the methods and uses provided herein may be a human individual.
[0198] As provided herein, bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) of any cause may be treated according to the methods and uses provided herein. For example, in some respects, bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) has been caused by hypogammaglobulinemia. In some respects, bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) has been caused by common variable immunodeficiency. In some respects, bronchiectasis (e.g., non-cystic fibrosis bronchiectasis) has been caused by alpha-1-antitrypsin deficiency.
[0199] The methods and uses provided herein may comprise the administration of a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprising a modified Fc region (e.g., AZD0292) to an individual. Administration may be intravenous. Administration may be subcutaneous.
[0200] The methods and uses provided herein are effective in the treatment of bronchiectasis (e.g., non-cystic fibrosis bronchiectasis). In some aspects of the methods and uses provided herein, the administration of a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprising a modified Fc region (e.g., Petition 870250102008, dated 07 / 11 / 2025, p. 78 / 142 70 / 106 AZD0292) reduces Pseudomonas aeruginosa in sputum cultures obtained from the individual, for example, compared to Pseudomonas aeruginosa in sputum cultures obtained from the individual before administration. The reduction may occur, for example, within 12 weeks of the first administration of the bispecific antibody, within 8 weeks of the first administration of the bispecific antibody, or within 4 weeks of the first administration of the bispecific antibody. In some aspects of the methods and uses provided herein, administration of a bispecific antibody that specifically binds to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprising a modified Fc region (e.g., AZD0292) decreases the individual's antibiotic use, for example, compared to the individual's use before administration.In some aspects of the methods and uses provided herein, administration of a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa (e.g., AZD0292) eradicates Pseudomonas aeruginosa in the individual.
[0201] The methods and uses provided herein may include administering a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292) to an individual in combination with an antibiotic. In some respects, the methods and uses provided herein comprise the administration of a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and that comprises a modified Fc region (e.g., AZD0292) to an individual in combination with an aminoglycoside, a ticarcillin, a ureidopenicillin, a ciprofloxacin, a cefepime, a gentamicin, an amikacin, a tobramycin, a ceftazidime, an aztreonam, a cefotaxime, a meropenem, a polymyxin B, or any combination thereof. Petition 870250102008, dated 07 / 11 / 2025, page 79 / 142 71 / 106 b. Methods and uses of bispecific anti-Pseudomonas antibodies with modified Fc regions in the prevention or treatment of nosocomial infections.
[0202] This disclosure provides a method for preventing nosocomial infection in a susceptible human individual, wherein the method includes administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprising a modified Fc region (e.g., AZD0292). A susceptible human individual is a person who is at risk of contracting a nosocomial infection but at the time of administration does not have an infection or does not exhibit symptoms of an infection; or a person who has contracted a hospital-acquired infection requiring intervention or mitigation. The method further includes monitoring the individual for symptoms after administration of the bispecific antibody for, for example, 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 21 days, 28 days, or 30 days. In one aspect, the method involves monitoring the individual for symptoms for at least about 21 days or more from the day of administration.Nosocomial infections are defined elsewhere herein and include, for example, pneumonia, bacteremia, bone infection, joint infection, skin infection, burn infection, wound infection, peritonitis, sepsis, and / or an abscess. The symptoms associated with nosocomial infections, for example, pneumonia, are known in the art. In certain respects, nosocomial infection is caused by, or exacerbated by, P. aeruginosa. According to this method, the human subject is treated correctly, for example, 1 day, 3 days, 5 days, 8 days, 10 days, 15 days, 21 days, 28 days, or 30 days after administration, the subject remains symptom-free (if the subject was symptom-free at the time of administration) or exhibits less severe symptoms than would be expected if they had not been treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292).In one respect, the human individual is treated correctly if, 21 days after administration, the... Petition 870250102008, dated 07 / 11 / 2025, pp. 80 / 142 72 / 106 The individual remains symptom-free (if the individual is symptom-free at the time of administration) or exhibits less severe symptoms than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292). In another aspect, the human individual is treated correctly if, 28 or 30 days after administration, the individual remains symptom-free (if the individual is symptom-free at the time of administration) or exhibits less severe symptoms than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292).
[0203] In another aspect, this disclosure provides a method of preventing or treating pneumonia, for example, hospital-acquired or non-hospital-acquired pneumonia in a susceptible human individual, wherein the method involves administering to the individual a bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa and comprising a modified Fc region (e.g., AZD0292). In certain aspects, the pneumonia is nosocomial or iatrogenic. A susceptible human individual is a person who is at risk of contracting pneumonia but at the time of administration does not have symptoms of pneumonia; or a person who has contracted pneumonia requiring intervention or mitigation. The method further includes monitoring the individual for symptoms of pneumonia after administration of the bispecific antibody for, for example, 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 21 days, 28 days, or 30 days.In one aspect, the method involves monitoring the individual for symptoms for at least approximately 21 days from the day of administration. The symptoms associated with pneumonia are known in the art. In certain aspects, pneumonia is caused by, or exacerbated by, P. aeruginosa. According to this method, the human individual is treated correctly, for example, at 1 day, 3 days, 5 days, 8 days, 10 days, 15 days, 21 days, 28 days, or 30 days after administration, the individual remains symptom-free. Petition 870250102008, dated 07 / 11 / 2025, page 81 / 142 73 / 106 of symptoms (if the individual was symptom-free at the time of administration) or exhibits less severe symptoms than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292). In one respect, the human individual is treated correctly if, 7 days after administration, the individual remains symptom-free (if the individual was symptom-free at the time of administration) or exhibits less severe symptoms than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292).In one aspect, the human subject is treated correctly if, 21 days after administration, the subject remains symptom-free (if the subject is symptom-free at the time of administration) or exhibits symptoms that are less severe than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292). In another aspect, the human subject is treated correctly if, 28 or 30 days after administration, the subject remains symptom-free (if the subject is symptom-free at the time of administration) or exhibits symptoms that are less severe than would be expected if not treated with a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292).
[0204] In another aspect, this disclosure provides a method of preventing or treating a disease caused by Pseudomonas aeruginosa, for example, pneumonia, tracheobronchitis, bacteremia, endocarditis, meningitis, otitis media, bacterial keratitis, endophthalmitis, osteomyelitis, gastrointestinal disease, skin infection, septicemia, or any combination thereof, in a susceptible human individual. In certain respects, the disease caused by Pseudomonas aeruginosa is nosocomial or iatrogenic. A susceptible human individual is a person who is at risk of contracting a disease that is treatable or preventable by the methods Petition 870250102008, dated 07 / 11 / 2025, p. 82 / 142 74 / 106 provided here, but at the time of administration does not present symptoms of the disease; or a person who has contracted a disease caused by Pseudomonas aeruginosa that requires treatment, intervention or mitigation.
[0205] The methods provided here are suitable for use with susceptible human patients, as described elsewhere herein. Examples include individuals who are about to be hospitalized, are currently hospitalized, have recently been hospitalized, are about to be, are currently or have recently been on a mechanical ventilator, or a combination thereof. Hospitalization, in some cases, may be in an intensive care unit (ICU). Mechanical ventilation, if necessary, may occur via intubation, for example, via an endotracheal or nasotracheal tube or via a tracheostomy. Patients who are about to be, are currently, or have recently been on mechanical ventilation may have an increased risk of contracting a respiratory infection, for example, pneumonia, for example, Pseudomonas aeruginosa pneumonia.In situations where mechanical ventilation is indicated, the administration of a bispecific antibody, as provided by the methods disclosed, may reduce the risk of contracting pneumonia, for example, during mechanical ventilation, after mechanical ventilation is no longer required, or a combination thereof.
[0206] In certain aspects, the individual is colonized by Pseudomonas aeruginosa in the respiratory tract, for example, in the lower respiratory tract, at the time of administration of the bispecific antibody. In certain aspects, the individual's respiratory tract is colonized by P. aeruginosa one, two, three, or four days before administration of the bispecific antibody. Colonization can be measured, for example, by detecting P. aeruginosa in a tracheal aspirate within 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or 96 hours before administration of the bispecific antibody. In certain aspects of the methods provided here, the individual Petition 870250102008, dated 07 / 11 / 2025, page 83 / 142 75 / 106 did not receive antibiotics considered active against the strain of P. aeruginosa with which the individual is colonized prior to administration of the bispecific antibody. In certain respects, the individual's respiratory tract may be additionally colonized by Staphylococcus aureus at the time of administration of the bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292).
[0207] In certain aspects, the individual does not have symptoms of pneumonia at the time of administration of the bispecific antibody. Symptoms can be measured according to the Clinical Pulmonary Infection Score (CPIS). The absence of symptoms can be inferred, for example, if 24 hours before the administration of the bispecific antibody the individual has a CPIS of less than 6.
[0208] The methods provided here include monitoring an individual for disease symptoms, for example, symptoms of pneumonia, after administration of the bispecific antibody. In certain respects, the individual may be monitored for pneumonia by chest radiography, observation of respiratory signs or symptoms of pneumonia, microbiological confirmation of pneumonia, or any combination thereof. An individual may be determined to have pneumonia, for example, when a new or worsening infiltrate consistent with pneumonia is observed on a chest radiograph, when the individual exhibits at least two minor respiratory signs or symptoms or at least one major respiratory sign or symptom of pneumonia, when a sample obtained from the individual is positive for P. aeruginosa by culture, or any combination thereof. In certain respects, the sample is a respiratory secretion from the individual.A respiratory secretion can be obtained from expectorated sputum, by endotracheal aspiration, by bronchoscopy with bronchoalveolar lavage, by using a protected bronchial brushing sample from an intubated individual, or any combination thereof. Petition 870250102008, dated 07 / 11 / 2025, page 84 / 142 76 / 106
[0209] Minor respiratory signs or symptoms of pneumonia include, but are not limited to, a body temperature greater than about 38°C, a core body temperature less than about 35°C, a white blood cell count greater than about 10,000 cells per cubic millimeter (mm3), a white blood cell count less than about 4,500 cells per mm3, a banded neutrophil count greater than about 15%, production of new purulent endotracheal secretions or sputum, new auscultatory findings, dullness to percussion, a recent onset of cough, dyspnea, tachypnea, hypoxemia, or any combination thereof.The main respiratory signs or symptoms of pneumonia may include, but are not limited to, an acute change made to the ventilatory support system to increase oxygenation comprising a PaO2 / FiO2 ratio greater than approximately 240 mm Hg maintained for at least four hours, a decrease in the PaO2 / FiO2 ratio greater than approximately 50 mm Hg maintained for at least four hours, the need to initiate or restart mechanical ventilation in a non-mechanically ventilated individual, or any combination thereof. Microbiological confirmation of pneumonia may include, but is not limited to, a positive respiratory sample for P. aeruginosa by culture, a positive blood culture for P. aeruginosa, a positive pleural fluid aspirate or lung tissue culture for P. aeruginosa, or any combination thereof.
[0210] In certain respects, the methods provided by this disclosure may additionally include administering an antibiotic to the individual before, simultaneously with, and / or after the administration of the bispecific antibody. Suitable antibiotics may include, but are not limited to, aminoglycosides, ticarcillin, ureidopenicillins, ciprofloxacin, cefepime, gentamicin, amikacin, tobramycin, ceftazidime, aztreonam, cefotaxime, or any combination thereof. Appropriate dosages and duration of treatment can be readily determined by a healthcare professional. In certain respects, the strain of P. aeruginosa to which the individual is exposed Petition 870250102008, dated 07 / 11 / 2025, page 85 / 142 77 / 106 colonized individuals are sensitive to the antibiotic chosen for administration. In other respects, however, the P. aeruginosa strain with which the individual is colonized is resistant or partially resistant to one or more of the available antibiotics chosen for administration. IV. Methods for the production of bispecific anti-Pseudomonas antibodies
[0211] A bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292) of the revelation can be produced by any method known in the art for antibody synthesis, in particular, by chemical synthesis or by recombinant expression techniques.
[0212] The present disclosure also provides polynucleotides comprising a nucleic acid sequence encoding a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified IgG constant domain of the disclosure or an FcRn-binding fragment thereof (e.g., an Fc region or an Fc-hinge region), as well as vectors comprising said polynucleotides. In specific aspects, the present disclosure provides an isolated polynucleotide comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein. In some aspects, the isolated polynucleotide further comprises a nucleic acid molecule encoding the light chain of the bispecific antibody described herein.
[0213] The nucleotide sequence of the bispecific antibodies Psl and PcrV anti-Pseudomonas aeruginosa comprising the modified IgG constant domain and the polynucleotides encoding the same can be obtained by any methods known in the art, including general DNA sequencing methods, such as dideoxy chain termination (Sanger sequencing) and oligonucleotide initiation in combination with PCR, respectively.
[0214] The nucleotide sequence that codes for an antibody can be obtained from any information available to those skilled in the art (i.e., from Petition 870250102008, dated 07 / 11 / 2025, page 86 / 142 78 / 106 (Genbank, from the literature, or by routine cloning). If a clone containing a nucleic acid encoding a specific antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin can be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library or a cDNA library generated from nucleic acid, e.g., poly A+ RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using hybridizable synthetic primers with the 3' and 5' ends of the sequence or by cloning using a specific oligonucleotide probe for the specific gene sequence to identify, for example, a cDNA clone from a cDNA library encoding the antibody.The amplified nucleic acids generated by PCR can then be cloned into replicable cloning vectors using any well-known method in the art.
[0215] Once the antibody nucleotide sequence is determined, the antibody nucleotide sequence can be manipulated using well-known methods in the art for nucleotide sequence manipulation, for example, recombinant DNA techniques, site-directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated herein by reference in their entirety), to generate antibodies with a different amino acid sequence, for example, by introducing amino acid substitutions, deletions and / or insertions in the antibody epitope-binding domain regions, for example, in the antibody hinge Fc regions that are involved in the interaction with FcRn. They can Petition 870250102008, dated 07 / 11 / 2025, p. 87 / 142 79 / 106 antibodies can be generated with one or more modifications at amino acid residues 432 to 437 or at other locations.
[0216] In specific embodiments, the nucleic acid molecule encoding the heavy chain of the bispecific antibody has a sequence according to SEQ ID NO:45. In specific embodiments, the nucleic acid molecule encoding the light chain of the bispecific antibody has a sequence according to SEQ ID NO:46.
[0217] Recombinant expression of an antibody requires the construction of an expression vector containing a nucleotide sequence encoding the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or a portion thereof (optionally, but not necessarily, containing the variable region of the heavy or light chain) has been obtained, the vector for producing the antibody molecule can be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein expressing a polynucleotide containing an antibody encoding the nucleotide sequence are described here. Methods that are well known to those skilled in the art can be used to construct expression vectors containing antibody-coding sequences and suitable transcriptional and translational control signals.These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The discovery thus provides replicable vectors comprising a nucleotide sequence encoding the constant region of the antibody molecule with one or more modifications to the amino acid residues involved in the interaction with FcRn (see, for example, PCT publication WO 86 / 05807; PCT publication WO 89 / 01036; and US patent no. 5,122,464). The nucleotide sequence encoding the heavy chain variable region, the light chain variable region, the heavy chain and light chain variable regions, a fragment. Petition 870250102008, dated 07 / 11 / 2025, page 88 / 142 80 / 106 epitope-binding regions of the heavy and / or light chain variable region or one or more complementarity-determining regions (CDRs) of an antibody can be cloned into this vector for expression.
[0218] Thus, in some aspects provided herein, the present disclosure relates to a vector comprising (i) a nucleic acid molecule encoding the heavy chain of the bispecific antibody, or (ii) a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein and a nucleic acid molecule encoding the light chain of the bispecific antibody described herein. In some aspects, the present disclosure relates to a pair of vectors, wherein the first vector of the pair of vectors comprises a nucleic acid molecule encoding the heavy chain of the bispecific antibody described herein, and the second vector of the pair of vectors comprises a nucleic acid molecule encoding the light chain of the bispecific antibody described herein. In specific embodiments, the nucleic acid molecule encoding the heavy chain of the bispecific antibody has a sequence according to SEQ ID NO:45.In specific embodiments, the nucleic acid molecule encoding the bispecific antibody light chain has a sequence corresponding to SEQ ID NO:46.
[0219] The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody with an increased affinity for FcRn and an increased in vivo half-life. Thus, development includes host cells containing a polynucleotide encoding an antibody, a constant domain or an FcRn-binding fragment thereof with one or more modifications at amino acid residues 432 to 437 or at other locations, optionally functionally linked to a heterologous promoter.
[0220] Several host expression vector systems can be used to express the antibody molecules of the revelation. These systems of Petition 870250102008, dated 07 / 11 / 2025, page 89 / 142 81 / 106 Host expression vectors represent vehicles by which coding sequences of interest can be produced and subsequently purified, but they also represent cells that, when transformed or transfected with the appropriate nucleotide coding sequences, can express a developing antibody molecule in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., E. coli and B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing antibody-coding sequences; yeast (e.g., Saccharomyces and Pichia) transformed with recombinant yeast expression vectors containing antibody-coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody-coding sequences;Plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; and tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody-coding sequences; and mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3, and NS0 cells) harboring recombinant expression constructs containing promoters derived from mammalian cell genomes (e.g., metallothionein promoter) or mammalian viruses (e.g., adenovirus late promoter);the 7.5K promoter of the vaccinia virus). Bacterial cells such as Escherichia coli, and eukaryotic cells, which are well suited for the expression of whole recombinant antibody molecules, are used for the expression of a recombinant antibody molecule. For example, mammalian cells, such as Chinese hamster ovary (CHO) cells, in conjunction with a vector, such as the main promoter element of the initial intermediate gene of human cytomegalovirus, is a system of; Petition 870250102008, dated 07 / 11 / 2025, pp. 90 / 142 82 / 106 effective expression for antibodies (Foecking et al., Gene, 45:101, 1986, and Cockett et al., Bio / Technology, 8:2, 1990).
[0221] In bacterial systems, a number of expression vectors can be advantageously selected depending on the intended use for the antibody molecule to be expressed. For example, when a large amount of this protein needs to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. These vectors include, but are not limited to, the E. coli pUR278 expression vector (Ruther et al., EMBO, 12:1791, 1983), in which the antibody coding sequence can be individually ligated into the vector structure with the lacZ coding region so that a fusion protein is produced; and pIN vectors (Inouye & Inouye, Nucleic Acids Res., 13:3101 to 3109, 1985 and Van Heeke & Schuster, J. Biol. Chem., 24:5503 to 5509, 1989).
[0222] In an insect system, the Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The antibody-coding sequence can be individually cloned into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under the control of an AcNPV promoter (e.g., the polyhedrin promoter).
[0223] In mammalian host cells, several virus-based expression systems can be used to express a developmental antibody molecule. In cases where an adenovirus is used as an expression vector, the antibody-coding sequence of interest can be ligated to an adenovirus transcription / translation control complex, for example, the late promoter and the tripartite initiation sequence. This chimeric gene can then be inserted into the adenovirus genome by recombination in vitro or in vivo. Insertion into a region Petition 870250102008, dated 07 / 11 / 2025, pp. 91 / 142 83 / 106 non-essential parts of the viral genome (e.g., El or E3 region) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:355-359, 1984). Specific initiation signals may also be required for the efficient translation of inserted antibody-coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translation control signals and initiation codons can be of various origins, both natural and synthetic. Expression efficiency can be increased by the inclusion of suitable transcription enhancers, transcription terminators, etc. (see, e.g., Bitter et al., Methods in Enzymol)., 153:516 a 544, 1987).
[0224] In addition, a host cell strain can be chosen that modulates the expression of antibody sequences or modifies and processes the antibody in the specific desired manner. These modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for antibody function. Different host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Suitable cell lines or host systems can be chosen to ensure correct modification and processing of the expressed antibody. For this purpose, eukaryotic host cells that possess the cellular machinery for proper primary transcript processing, glycosylation, and gene product phosphorylation can be used.These mammalian host cells include, but are not limited to, CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, W138 and, in particular, myeloma cells such as NS0 cells and related cell lines, see, for example. Petition 870250102008, dated 07 / 11 / 2025, pp. 92 / 142 84 / 106 example, Morrison et al., US patent no. 5,807,715, which is incorporated herein by reference in its entirety.
[0225] For long-term, high-yield production of recombinant antibodies, stable expression is preferred. For example, cell lines that stably express the antibody molecule can be manipulated. Instead of using expression vectors containing viral origins of replication, host cells can be transformed with DNA controlled by suitable expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.) and a selectable marker. After the introduction of the foreign DNA, the manipulated cells are allowed to grow for 1–2 days in an enriched medium and then transferred to a selective medium.The selectable marker on the recombinant plasmid confers resistance to selection and enables cells to stably integrate the plasmid into their chromosomes and grow to form foci that, in turn, can be cloned and expanded into cell lines. This method can be advantageously used to manipulate cell lines that express the antibody molecule. These manipulated cell lines can be particularly useful in screening and evaluating compositions that interact directly or indirectly with the antibody molecule.
[0226] Several selection systems can be used, including, but not limited to, herpes simplex virus thymidine kinase (Wigler et al., Cell, 11:223, 1977), hypoxanthineguanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:202, 1992), and adenine phosphoribosyltransferase (Lowy et al., Cell, 22:8 to 17, 1980) can be employed in tk-, hgprt- or aprt- cells, respectively. Furthermore, resistance to antimetabolites can be used as a basis for selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA, 77:357, 1980 and O'Hare et al., Proc. Natl. Acad. Sci. USA, Petition 870250102008, dated 07 / 11 / 2025, pp. 93 / 142 85 / 106 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, Biotherapy, 3:87 to 95, 1991; Tolstoshev, Ann. Rev. Pharmacol. Toxicol., 32:573 to 596, 1993; Mulligan, Science, 260:926 to 932, 1993; and Morgan and Anderson, Ann. Rev. Biochem., 62: 191 to 217, 1993; and May, TIB TECH, 11(5):l55-215, 1993); and hygro, which confers resistance to hygromycin (Santerre et al., Gene, 30:147, 1984). Methods commonly known in recombinant DNA technology can be routinely applied to select the desired recombinant clone, and these methods are described, for example, in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; in chapters 12 and 13, Dracopoli et al.(eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY; and Colberre-Garapin et al., J. Mol. Biol., 150:1, 1981, which are incorporated here by reference in their entirety).
[0227] The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, 1987, The use of gene amplification-based vectors for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. Academic Press, New York, USA). When a marker in the antibody-expressing vector system is amplifiable, increasing the level of inhibitor present in the host cell culture will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, antibody production will also increase (Crouse et al., Mol., Cell. Biol., 3:257, 1983).
[0228] The host cell can be co-transfected with two revelation expression vectors, the first vector encoding a heavy chain-derived polypeptide and the second vector encoding a light chain-derived polypeptide. The two vectors can contain identical selectable markers that enable the Petition 870250102008, dated 07 / 11 / 2025, pp. 94 / 142 86 / 106 equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector that encodes and is capable of expressing both heavy and light chain polypeptides can be used. In such situations, the light chain should be positioned before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature, 322:52, 1986; and Kohler, Proc. Natl. Acad. Sci. USA, 77:2 197, 1980). The coding sequences for the heavy and light chains can comprise cDNA or genomic DNA.
[0229] Once a bispecific anti-Pseudomonas antibody comprising a modified Fc region (e.g., AZD0292) of the present development has been produced by recombinant expression, it can be purified by any method known in the art for the purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after purification of Protein A and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for protein purification. Furthermore, the present development antibodies or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification. V. Pharmaceutical compositions
[0230] The pharmaceutical compositions used in this disclosure may comprise bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies comprising modified Fc regions (e.g., AZD0292) and pharmaceutically acceptable carriers well known to those skilled in the art. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Petition 870250102008, dated 07 / 11 / 2025, pp. 95 / 142 87 / 106
[0231] The route of administration of a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody may be, for example, parenteral. The term parenteral, as used herein, includes, for example, intravenous and subcutaneous administration. Consequently, a pharmaceutical composition comprising a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified Fc region (e.g., AZD0292) may be formulated for intravenous administration. In some respects, a pharmaceutical composition comprising a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified Fc region (e.g., AZD0292) may be formulated for subcutaneous administration. A suitable form of administration would be an injectable solution.
[0232] Pharmaceutical compositions comprising bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies comprising modified Fc regions (e.g., AZD0292) may be administered and / or formulated, for example, for the treatment of a developing disease.
[0233] Bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies comprising a modified Fc region (e.g., AZD0292) can be administered in a pharmaceutically effective amount for in vivo treatment or prevention of Pseudomonas aeruginosa infection.
[0234] As provided herein, pharmaceutical compositions comprising Psl and PcrV bispecific anti-Pseudomonas aeruginosa antibodies comprising a modified region (e.g., AZD0292) may be formulated for administration in combination with an antibiotic. In some respects, the bispecific antibodies are formulated for administration in combination with an aminoglycoside, a ticarcillin, a ureidopenicillin, a ciprofloxacin, a cefepime, a gentamicin, an amikacin, a tobramycin, a ceftazidime, a Petition 870250102008, dated 07 / 11 / 2025, pp. 96 / 142 88 / 106 aztreonam, cefotaxime, meropenem, polymyxin B, or any combination thereof. VI. Kits comprising bispecific anti-Pseudomonas antibodies with modified Fc regions
[0235] The disclosure also provides a pharmaceutical package or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the disclosure. Optionally, such container(s) may be associated with a notification in the form prescribed by a government agency that regulates the manufacture, use or marketing of pharmaceutical or biological products, such notification reflecting the agency's approval for the manufacture, use or marketing for administration in humans.
[0236] The present disclosure provides kits that can be used in the above methods. In one aspect, a kit comprises a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified Fc region of the disclosure (e.g., AZD0292), optionally in a purified form, in one or more containers. In a specific aspect, the kits of the present disclosure contain a substantially isolated antigen or combination of antigens (e.g., PcrV and Psl) as a control. Optionally, the kits of the present disclosure further comprise a control antibody, a fusion protein, or a conjugate molecule that does not react with the antigen included in the kit.In another specific aspect, the kits of the present disclosure contain a means for detecting the binding of a bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified Fc region of disclosure (e.g., AZD0292) to an antigen (e.g., the bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibody comprising a modified Fc region of disclosure (e.g., AZD0292) may be conjugated to a detectable substrate, such as a fluorescent compound, an enzymatic substrate, a radioactive compound, or a luminescent compound, or a... Petition 870250102008, dated 07 / 11 / 2025, p. 97 / 142 89 / 106 second antibody that recognizes that the first antibody can be conjugated to a detectable substrate). In specific aspects, the kit may include a recombinantly produced or chemically synthesized antigen or a combination of antigens. The antigen(s) supplied in the kit may also be fixed to a solid support. In a more specific aspect, the detection means of the kit described above include a solid support to which an antigen or a combination of antigens is fixed. This kit may also include an unbound anti-human antibody labeled with a reporter. In this aspect, the binding of the antibody to the antigen can be detected by the binding of said labeled reporter antibody. VII. Immunoassays
[0237] Bispecific Psl and PcrV anti-Pseudomonas antibodies comprising a modified Fc region of revelation (e.g., AZD0292) can be tested for immunospecific binding by any method known in the art. Immunoassays that can be used include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme-linked immunosorbent assay), sandwich immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name just a few. These assays are routine and well-known in the art (see, for example, Ausubel et al., eds, Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, USA Vol.1 (1994), which is incorporated herein by reference in its entirety). Exemplary immunoassays are briefly described below (but are not intended as a limitation).
[0238] There are several methods available for measuring the affinity of an antibody-antigen interaction, but relatively few for determining rate constants. A Petition 870250102008, dated 07 / 11 / 2025, pp. 98 / 142 90 / 106 Most methods rely on labeling antibodies or antigens, which inevitably complicates routine measurements and introduces uncertainties in the measured quantities. Antibody affinity can be measured by several methods, including OCTET®, BIACORE®, ELISA, and FACS.
[0239] The OCTET® system uses biosensors in a 96-well plate format to report kinetic analysis. Protein binding and dissociation events can be monitored by measuring the binding of a protein in solution to a second protein immobilized on the FortéBio biosensor. In the case of measuring the binding of bispecific Psl and PcrV anti-Pseudomonas antibodies with Fc region modifications by immobilization on OCTET® tips followed by antibody binding analysis, the association and dissociation of the antibody to immobilized bispecific Psl and PcrV anti-Pseudomonas antibodies with Fc region modifications is then detected by the instrument sensor. The data are then collected and exported to GraphPad Prism for affinity curve fitting.
[0240] Surface plasmon resonance (SPR), as performed on BIACORE®, offers several advantages over conventional methods for measuring the affinity of antibody-antigen interactions: (i) there is no need to label either the antibody or the antigen; (ii) antibodies do not need to be pre-purified, the cell culture supernatant can be used directly; (iii) real-time measurements, enabling rapid semi-quantitative comparison of different monoclonal antibody interactions, are permitted and are sufficient for many evaluation purposes; (iv) the biospecific surface can be regenerated so that a series of different monoclonal antibodies can be easily compared under identical conditions; (v) analytical procedures are fully automated and an extensive series of measurements can be performed without user intervention. Petition 870250102008, dated 07 / 11 / 2025, pp. 99 / 142 91 / 106 BIA Applications Handbook, version AB (reprinted in 1998), BIACORE® code no. BR-1001-86; BIA Technology Handbook, version AB (reprinted in 1998), BIACORE® code no. BR-1001-84.
[0241] SPR-based binding studies require that one member of a binding pair be immobilized on a sensor surface. The immobilized binding partner is called the ligand. The binding partner in solution is called the analyte. In some cases, the ligand is indirectly attached to the surface by binding to another immobilized molecule, which is called the capture molecule. The SPR response reflects a change in mass concentration on the detector surface as analytes bind or dissociate.
[0242] Based on SPR, BIACORE® real-time measurements monitor interactions directly as they happen. The technique is well suited for determining kinetic parameters. Comparative affinity classification is extremely simple to perform, and kinetic and affinity constants can be derived from sensorgram data.
[0243] When the analyte is injected in a distinct pulse through a ligand surface, the resulting sensorgram can be divided into three essential phases: (i) Association of analyte with ligand during sample injection; (ii) Equilibrium or steady state during sample injection, where the rate of analyte binding is balanced by the dissociation of the complex; (iii) Dissociation of analyte from the surface during buffer flow.
[0244] The association and dissociation phases provide information about the kinetics of the analyte-ligand interaction (ka and kd, the rates of formation and dissociation of complexes, kd / ka = Kd). The equilibrium phase provides information about the affinity of the analyte-ligand interaction (Kd).
[0245] The BIA evaluation software provides comprehensive facilities for curve fitting using numerical integration and global fitting algorithms. With the Petition 870250102008, dated 07 / 11 / 2025, pp. 100 / 142 92 / 106 Proper analysis of the data, separate rate and affinity constants for interaction can be obtained from simple BIACORE® investigations. The range of affinities measurable by this technique is very wide, in the range of mM to pM.
[0246] Epitope specificity is an important characteristic of a monoclonal antibody. Epitope mapping with BIACORE®, in contrast to conventional techniques using radioimmunoassay, ELISA, or other surface adsorption methods, does not require labeling or purified antibodies and enables multi-site specificity testing using a sequence of multiple monoclonal antibodies. In addition, a large number of analyses can be processed automatically.
[0247] Paired binding experiments test the ability of two MAbs to bind simultaneously to the same antigen. MAbs directed against separate epitopes will bind independently, while MAbs directed against identical or closely related epitopes will interfere with each other's binding. These binding experiments with BIACORE® are easy to perform.
[0248] For example, a capture molecule can be used to bind the first MAb, followed by the addition of antigen and the second MAb sequentially. The sensorgrams will reveal: 1. how much of the antigen binds to the first MAb, 2. to what extent the second MAb binds to the surface-bound antigen, 3. whether the second MAb does not bind, and whether reversing the order of the paired tests alters the results.
[0249] Peptide inhibition is another technique used for epitope mapping. This method can complement paired antibody binding studies and can relate functional epitopes to structural features when the primary antigen sequence is known. Peptides or antigen fragments are tested for inhibition of binding of different MAbs to the immobilized antigen. Peptides that interfere with the binding of a given MAb are considered structurally related to the epitope defined by that MAb. Petition 870250102008, dated 07 / 11 / 2025, pp. 101 / 142 93 / 106 VIII. Diagnostic uses
[0250] In some respects provided herein, the bispecific Psl and PcrV anti-Pseudomonas aeruginosa antibodies with modified Fc regions are useful for detecting the presence of Pseudomonas aeruginosa Psl and / or PcrV in a sample or an individual. The term detection, as used herein, encompasses quantitative or qualitative detection. Methods of using the antibodies of this disclosure for diagnostic purposes are provided herein, such as the detection of Pseudomonas aeruginosa Psl and / or PcrV in an individual or in tissue samples derived from an individual. In some respects, the individual is a human being. The detection method may involve quantification of the antibody bound to the antigen. Detection of antibodies in biological samples may occur with any method known in the art, including immunofluorescence microscopy, immunocytochemistry, immunohistochemistry, ELISA, FACS analysis, immunoprecipitation, or micropositron emission tomography.In certain aspects, the antibody is radiolabeled, for example, with 18F, and subsequently detected using micropositron emission tomography analysis. Antibody binding can also be quantified in a patient by non-invasive techniques such as positron emission tomography (PET), X-ray computed tomography, single-photon emission computed tomography (SPECT), computed tomography (CT), and computed axial tomography (CAT). ***
[0251] The practice of disclosure will employ, except where otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the scope of the practice of the technique. These techniques are explained in full in the literature. See, for example, Molecular Cloning: A Laboratory Manual, 2nd ed., Petition 870250102008, dated 07 / 11 / 2025, pp. 102 / 142 94 / 106 Sambrook et al., ed., Cold Spring Harbor Laboratory Press: (1989); Molecular Cloning: A Laboratory Manual, Sambrook et al., ed., Cold Springs Harbor Laboratory, New York, EUA (1992), DNA Cloning, D. N. Glover ed., Volumes I e II (1985); Oligonucleotide Synthesis, M. J. Gait ed., (1984); Mullis et al. patente US n°: 4683195; Nucleic Acid Hybridization, B. D. Hames & S. J. Higgins eds. (1984); Transcription And Translation, B. D. Hames & S. J. Higgins eds. (1984); Culture Of Animal Cells, R. I. Freshney, Alan R. Liss, Inc., (1987); Immobilized Cells And Enzymes, IRL Press, (1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); o tratado, Methods In Enzymology, Academic Press, Inc., N.Y.; Gene Transfer Vectors For Mammalian Cells, J. H. Miller e M. P. Calos eds., Cold Spring Harbor Laboratory (1987); Methods In Enzymology, volumes 154 e 155 (Wu et al. eds.); Immunochemical Methods In Cell And Molecular Biology, Mayer e Walker, eds., Academic Press, Londres (1987); Handbook Of Experimental Immunology, volumes I a IV, D. M. Weir e C. C. Blackwell, eds., (1986); Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); e em Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989).
[0252] General principles of antibody manipulation are presented in Antibody Engineering, 2nd edition, CAK Borrebaeck, Ed., Oxford Univ. Press (1995). General principles of protein manipulation are presented in Protein Engineering, A Practical Approach, Rickwood, D., et al., Eds., IRL Press at Oxford Univ. Press, Oxford, Eng. (1995). The general principles of antibodies and antibody-hapten binding are presented in: Nisonoff, A., Molecular Immunology, 2nd ed., Sinauer Associates, Sunderland, MA, USA (1984); and Steward, MW, Antibodies, Their Structure and Function, Chapman and Hall, New York, NY, USA (1984). In addition, standard methods in immunology known in the art and not specifically described are generally followed, as in Current Protocols in Immunology, John Wiley & Sons, New York, USA; Stites et al. (eds), Basic and Clinical -Immunology (8a Petition 870250102008, dated 07 / 11 / 2025, pp. 103 / 142 95 / 106 ed.), Appleton & Lange, Norwalk, CT (1994) e Mishell e Shiigi (eds), Selected Methods in Cellular Immunology, W.H. Freeman and Co., New York, EUA (1980).
[0253] Os trabalhos de referência padrão que apresentam princípios gerais de imunologia incluem Current Protocols in Immunology, John Wiley & Sons, New York, EUA; Klein, J., Immunology: The Science of Self-Nonself Discrimination, John Wiley & Sons, New York, EUA (1982); Kennett, R., et al., eds., Monoclonal Antibodies, Hybridoma: A New Dimension in Biological Analyses, Plenum Press, New York, EUA (1980); Campbell, A., Monoclonal Antibody Technology em Burden, R., et al., eds., Laboratory Techniques in Biochemistry and Molecular Biology, volume 13, Elsevere, Amsterdam (1984), Kuby Immunnology 4aed. Ed. Richard A. Goldsby, Thomas J. Kindt e Barbara A. Osborne, H. Freemand & Co. (2000); Roitt, I., Brostoff, J. and Male D., Immunology 6aed. London: Mosby (2001); Abbas A., Abul, A. e Lichtman, A., Cellular and Molecular Immunology Ed.5, Elsevier Health Sciences Division (2005); Kontermann and Dubel, Antibody Engineering, Springer Verlan (2001); Sambrook and Russell, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press (2001); Lewin, Genes VIII, Prentice Hall (2003); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988); Dieffenbach and Dveksler, PCR Primer Cold Spring Harbor Press (2003). Examples
[0254] The present revelation is illustrated by the following examples. It should be understood that the examples, materials, quantities, and specific procedures are to be interpreted broadly in accordance with the scope and spirit of the revelation as presented here. Example 1: Construction of AZD0292 and opsonophagocytic killing and anticytotoxicity activity.
[0255] The gremubamab antibody (also known as MEDI3902) is a bispecific antibody containing an anti-Psl antigen-binding domain and a Petition 870250102008, dated 07 / 11 / 2025, pp. 104 / 142 96 / 106 anti-PcrV antigen-binding domain. Gremubamab antibody sequences are provided above in Table 1. A novel antibody, named AZD0292, was constructed using the same anti-Psl and anti-PcrV antigen-binding domains, but containing a half-life extension N3Y modification in the CH3 domain. The AZD0292 antibody was constructed as described in DiGiandomenico et al., 2014 (Sci. Trans. Med.), except that the wild-type sequence MHEALHNHYTQKSLSLS (SEQ ID NO:32) was replaced by that of a modified Fc subsequence comprising the N3Y mutations (underlined): MHEACSYHLCQKSLSLS (SEQ ID NO:33).
[0256] Monoclonal antibodies targeting Psl and PcrV are known to mediate opsonophagocytic killing (OPK) and anticytotoxic activity, respectively, against P. aeruginosa. (See, DiGiandomenico et al., 2014 Sci. Trans. Med.). Therefore, AZD0292 was evaluated for its ability to mediate complement-dependent opsonophagocytic killing activity of a luminescent P. aeruginosa strain (DiGiandomenico et al., 2014 Sci. Trans. Med) compared to gremubamab, anti-Psl monoclonal antibody (mAb) Psl0096, anti-PcrV mAb V2L2-MD, and a control IgG. This assay was performed in a 96-well plate using 0.025 ml of each component; Luminescent strain of P. aeruginosa PAO1 (DiGiandomenico et al., 2012 J. Exp. Med), diluted neonatal rabbit serum (Cedar Lane), differentiated HL-60 cells, and monoclonal antibody.Data were acquired using a Tecan Spark multimode microplate reader (Tecan) and then subsequently plotted as percentage of opsonophagocytic killing compared to a non-antibody control at various temperatures. Results are shown in Figure 1A. AZD0292, gremubamab, and anti-Psl mAb Psl0096 mediated similar OPK activity against P. aeruginosa. As expected, no opsonophagocytic killing activity was observed with anti-PcrV V2L2-MD mAb or with the control IgG antibodies. Petition 870250102008, dated 07 / 11 / 2025, pp. 105 / 142 97 / 106
[0257] AZD0292 was also evaluated for its anticytotoxic activity. This assay was performed as described in DiGiandomenico et al., 2014., Sci. Trans. Med. The tested antibodies were first added to A549 cells (2x10⁴ cells / well), which were seeded in 96-well white plates (provided by Nunc Nunclon Delta) in Dulbecco-modified Eagle medium plus 10% fetal bovine serum. The logarithmic phase P. aeruginosa 6077 strain, which is capable of expressing Exoenzyme U, was then added at a desired multiplicity of infection (MOI) of 10⁶ and incubated for 2 hours at 37 °C with 5% CO₂. Subsequently, lactate dehydrogenase release from the lysed cells was measured. The data were acquired using a Tecan Spark multimode microplate reader (Tecan). The results are shown in Figure 1B.In this assay, AZD0292, gremubamab, and the anti-PcrV mAb V2L2-MD prevented cell death with similar efficacy, while an IgG control and the anti-Psl mAb Psl0096 did not have the expected protective activity.
[0258] These results indicate that AZD0292 and gremubamab function equivalently in both anti-Psl and anti-PcrV functional activity assays.
[0259] Next, to test the impact of different half-life extension technologies, AZD0292 was evaluated for its ability to mediate complement-dependent opsonophagocytic killing activity of a luminescent P. aeruginosa strain (DiGiandomenico et al., 2014 Sci. Trans. Med) compared to gremubamab, afucosylated (Afuc) versions of gremubamab with YTE half-life extension (SEQ ID NO:43) and without YTE half-life extension (M252Y / S254T / T256E substitutions in the Fc region, numbering according to Kabat) and a control IgG. A Chinese hamster ovary (CHO) temporary expression system was used to generate afucosylated IgG. Several methods are now established for generating recombinant afucosylated proteins. For example, fucose titration in cell culture media (Louie et al Biotechnol Bioeng. Petition 870250102008, dated 07 / 11 / 2025, pp. 106 / 142 98 / 106 March 2017;114(3):632 to 644), co-expression of GDP-6-deoxy-D-lixo-4-hexulose reductase (von Horsten et al Glycobiology. December 2010;20(12):1607 to 1618), co-expression of an intrabody anti-FUT8 (Joubert et al Biotechnol Bioeng. August 2022;119(8):2206 to 2220), FUT8 inactivation cell line (Yamane Ohnuki et al Biotechnol Bioeng. September 5, 2004;87(5):614 to 622; Malphettes et al Biotechnol Bioeng. August 1, 2010;106(5):774 to 783) and other strategies (Pereira et al MAbs.
[0260] This assay was performed in a 96-well plate using 0.025 ml of each component; luminescent P. aeruginosa PAO1 strain (DiGiandomenico et al., 2012 J. Exp. Med), diluted neonatal rabbit serum (Cedar Lane), differentiated HL60 cells, and monoclonal antibody. Data were acquired using a Tecan Spark multimode microplate reader (Tecan) and then subsequently plotted as percentage of kills compared to an antibody-free control at various temperatures. The results are shown in Figure 2. AZD0292, gremubamab, and gremubamab-Afuc mediated similar OPK activity against P. aeruginosa. Whereas, Gremubamab-Afuc-YTE exhibited reduced activity compared to AZD0292, gremubamab, and gremubamab-Afuc. No opsonophagocytic killing activity was observed with the control IgG antibody.
[0261] These results surprisingly indicate that different half-life extension technologies that modify the Fc region can affect the antibody's opsonophagocytic killing activity. Although modifying the YTE half-life extension caused a significant decrease in activity (noting that the activity of afucosylated gremubamab was similar to gremubamab), modifying the N3Y half-life extension did not affect opsonophagocytic killing activity. Petition 870250102008, dated 07 / 11 / 2025, pp. 107 / 142 99 / 106 Example 2: AZD0292 increased serum exposure compared to gremubabamab.
[0262] The N3Y modification of AZD0292 enables greater binding affinity to the neonatal Fc receptor (FcRn), which functions as a recycling receptor responsible for maintaining IgG in circulation. To confirm that AZD0292 exhibited increased exposure versus gremubamab, the pharmacokinetics of each molecule were compared in a human FcRn transgenic mouse model Tg32.
[0263] In the pharmacokinetic analysis, AZD0292 and gremubamab (10 mg / kg) were both administered intravenously to 7-week-old mice, followed by blood sampling at 1, 4, 12, 54, 72, and 102 hours, as well as 7, 9, 11, 14, 17, 21, 24, 28, 35, and 42 days after antibody administration. Blood was collected in BD microcontainer blood collection tubes, and serum was subsequently processed by centrifugation at 500 x g for approximately 10 minutes. The processed serum was stored at -80°C until antibody quantification.
[0264] Quantification of gremubamab and AZD0292 in mouse sera was performed using antigen-specific ELISA. Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated overnight at 4 °C with an anti-idiotype antibody targeting the anti-PcrV portion of gremubamab and AZD0292. After washing with STF containing 0.1% Tween 20 (wash buffer), the plates were blocked for 1 hour at room temperature (RT) with STF + 5% BSA. After three washes with wash buffer, the plates were incubated with mouse sera diluted in STF. AZD0292 or gremubamab were then used as standards.
[0265] After a 1.5 hour incubation period while agitating (200 rpm) at room temperature (RT), the plates were washed and incubated for 30 min with Petition 870250102008, dated 07 / 11 / 2025, pages 108 / 142 100 / 106 0.05 ml of an anti-idiotype antibody targeting the anti-Psl arm of Gremubamab / MEDI3902 and AZD0292 was added. After three washes with washing buffer, 0.05 ml of horseradish peroxidase-conjugated goat anti-human IgG (HRP) (1:10,000; Jackson Laboratories) was added and incubated for 30 minutes at RT. After washing, 0.05 ml of 3,3',5,5'-tetramethylbenzidine (TMB) (KPL) substrate was added and the reaction was stopped after approximately 10 minutes with 0.05 ml of 0.2 M H2SO4. The optical density at 450 nm (OD450) was measured using a spectrophotometer (Molecular Devices).
[0266] The results are shown in Figure 3. After administration of 10 mg / kg IV of AZD0292 and gremubamab, a 50% lower clearance was estimated for AZD0292 compared with gremubamab. Example 3: AZD0292 subjected to light and heat stress retains anti-Psl and anti-PcrV functional activity.
[0267] To determine whether AZD0292 maintained functional activity after exposure to light and heat stress conditions, its activity was evaluated in comparison with similarly treated gremubabamab in OPK and anticytotoxicity assays.
[0268] Accelerated light and heat stress stability assays were performed as described (Dippel et al., 2023 MABS). Briefly, in heat stress assays, antibodies were diluted to 1 mg / ml in STF (pH 7.2) and incubated for 2 weeks at 4 °C or 45 °C. In light stress assays, antibodies were formulated at 2.5 mg / ml in STF (pH 7.2), filled into 1 cc Schott glass vials, capped / sealed, and placed in an ICH-compliant photostability chamber (Caron Model 6545-2). Samples were exposed to cool white light at 3000 lux over 1 week, totaling an exposure of approximately 500,000 lux hours. Petition 870250102008, dated 07 / 11 / 2025, pp. 109 / 142 101 / 106
[0269] In OPK and anticytotoxicity assays, AZD0292 and gremubamab antibodies subjected to light and heat stress performed similarly to AZD0292 and gremubamab not subjected to stress. See Figures 4A and 4B. The percentage change in monomer, aggregate, and fragment formation compared to the unstressed material is shown in Table 2. Table 2. Antibody Photostability Accelerated heat stability Change in monomer (%) Change in aggregate (%) Change in fragment (%) Change in monomer (%) Change in aggregate (%) Change in fragment (%) Gremubamab 1.27 1.27 0.00 2.61 0.00 2.61 AZD0292 1.49 1.49 0.00 2.70 0.00 2.70
[0270] These data did not indicate a difference in the functional activity of AZD0292 subjected to stress and not subjected to stress or gremubabamab. Example 4: AZD0292 surprisingly demonstrates reduced aggregation.
[0271] Studies were carried out to assess whether there was any difference in product quality between clones expressing AZD0292 and MEDI3902 (specifically assessing aggregate levels, monomer levels, protein concentration and expressed titer).
[0272] In order to evaluate the effect of the N3Y mutation in AZD0292 on affinity product aggregate levels, a shake plate overgrow (SPOG) screening was performed. In the study, 384 clones were screened and the 96 best were selected based on their expressed titers. Aggregation analysis was performed on the 96 best clones using small-scale Protein A capture followed by high-throughput size exclusion chromatography (HTSEC). Petition 870250102008, dated 07 / 11 / 2025, pp. 110 / 142 102 / 106
[0273] For shake plate overgrowth screening, in summary, after clonal cell line expansion, the cell culture of each stable clone was seeded at 0.7 x 10⁵ cells / ml in a total volume of 350 μl in a 96-well deep plate and subjected to a 10-day fed-batch process using cell growth medium and bolus additions of nutrients and glucose. On day 10 of this fed-batch experiment, the cell culture of each stable clone evaluated was then harvested. Viable cell density and cell viability of each clone were measured.The cell culture medium was then clarified by centrifugation, and the supernatant samples were sent for rProtein titer analysis (quantified using high-performance liquid chromatography (HPLC) of protein A on an Agilent HP1100 or HP1200 (Agilent Technologies, Santa Clara, CA, USA) comparing the peak size of each sample with a calibration curve). The HTP aggregation analysis is described in more detail below.
[0274] Protein purification from 96-well deep plate cell culture was performed using 200 μl PhyTip volume columns containing 20 μl of ProPlus affinity resin (MabSelect SuRe™) (Biotage GB Limited, Hengoed, UK) operated on a Tecan Freedom EVO® 200 liquid handling robotic platform (TECAN Group Ltd.) with Freedom EVOware®, Version 2.7 (TECAN Group Ltd.).
[0275] Phosphate buffer saline solution was used as column equilibrium and buffer for the first washing step (wash 1), while the buffer for the second washing step (wash 2) was composed of 25 mM sodium acetate, 120 mM sodium chloride, pH 5.5. Elution was performed using 100 mM glycine buffer pH 2.6 or 25 mM sodium acetate buffer, pH 3.6. After purification, the samples were neutralized using 1 M Tris buffer pH 7.5. Petition 870250102008, dated 07 / 11 / 2025, pp. 111 / 142 103 / 106
[0276] Aggregation analysis was performed by high-throughput size exclusion chromatography (HTSEC) monitoring UV absorbance at 280 nm. The equipment and software packages for chromatography analysis were all purchased from Agilent Technologies Inc. and involved the Agilent 1260 Infinity II UHPLC system, including a degasser, quaternary pump, thermostated multisampler, and diode array detector (DAD) in conjunction with a multi-column compartment with a column selection valve. All parts of the UHPLC were joined by 1.6 mm OD, 0.12 μm ID stainless steel capillary tubing with stainless steel connections. System control and data analysis were performed using Agilent OpenLAB CDS ChemStation Edition, version C.01.07.HTSEC analysis was performed using an Acquity UPLC Protein BEH SEC 200 A, 1.7 μm (Waters) column with a 2.1 χ 150 mm (ID x length) and a mobile phase composed of 50 mM sodium phosphate, 450 mM arginine, pH 7.0. Data visualization and statistical analysis were performed using the JMP Pro16 (SAS) software package.
[0277] Figures 5A and 5B show bar graph representations of the data obtained from the study for the percentage of monomer (Figure 5A) and the percentage of higher molecular weight aggregate species (Figure 5B) for AZD0292 and MEDI3902. Monomer percentage refers to the expected monoclonal antibody (with 2 heavy chains and 2 light chains). Data for A5, A6, A9, B9, and E6 are missing due to insufficient sample availability for analysis. The data obtained from this study show that, surprisingly, AZD0292 had significantly fewer higher molecular weight aggregate species than MEDI3902. This demonstration across multiple expression clones indicates that the observation is not simply an artifact of a single clone, but rather a fundamental aspect of the N3Y mutations of AZD0292 compared to MEDI3902. Petition 870250102008, dated 07 / 11 / 2025, pp. 112 / 142 104 / 106
[0278] Another representation of these data from Figure 5B is shown in Figure 6. Figure 6 shows the % aggregation (percentage of high molecular weight species) for each clone. The light (fewer aggregates) to dark (more aggregates) coloration is proportional to the % of aggregates measured in each sample by HTSEC. This visual representation clearly demonstrates the surprising decrease in the % aggregation of AZD0292 compared to MEDI3902.
[0279] The data were plotted graphically in Figure 7 to assess the presence of any correlation between the percentage of high molecular weight species (e.g., aggregates), the mean concentration of the purified PhyTip Protein A sample, and the titer on the last day of the 96-well fed-batch plate bioreactor. However, no correlation was observed in the scatter plot matrix (Figure 7). These data indicate that aggregation is not induced by sample concentration levels across the evaluated range and that aggregation is not induced by the titer on the last day of the fed-batch process.
[0280] To further compare the levels of aggregates between clones expressing MEDI3902 and AZD0292, the data were tested by aligning with the normality assumption required to use the Student's t-test statistic. Both the Anderson-Darling and Shapiro-Wilk tests (Figures 8A and 8B for samples AZD0292 and MEDI3902, respectively) confirmed that the data are normally distributed (p-value > 0.05). The t-test approach used assumed equal variances based on a two-tailed F-test assessment, yielding a p-value > 0.05. The results of the T-test showed that the average levels of aggregation observed in clones expressing MEDI3902 versus AZD0292 are statistically significant (p-value < 0.05 based on the 95% confidence interval (Figure 8C)). On average, the observed difference was 2.99% fewer aggregates for AZD0292 samples compared to MEDI3902 samples (Figure 8C). Petition 870250102008, dated 07 / 11 / 2025, pp. 113 / 142 105 / 106
[0281] Figure 9A shows the % aggregation and Figure 9B shows the antibody titer levels for clones expressing AZD0292 and MEDI3902 measured in all samples and ordered from low to high aggregate levels (from left to right in Figure 9A with the titer level of the last day of the corresponding fed-batch below in Figure 9B for the same clone). Figure 9A shows reduced aggregation of AZD0292 samples compared to MEDI3902 samples. The data indicate that the decrease in aggregation for AZD0292 is not correlated with reductions in titer level.
[0282] Figure 10 shows the percentage of aggregate data for AZD0292 and MEDI3902 over three months at 40 °C. The increase in the percentage of aggregates for AZD0292 and MEDI3902 over time was comparable, indicating that both molecules (MEDI3902 and AZD0292) had similar degradation rates.
[0283] Overall, these results demonstrate that clones expressing AZD0292 had significantly fewer aggregates than those expressing MEDI3902. Although the average expression titer of clones expressing MEDI3902 is slightly higher than those expressing AZD0292, the difference is not significant. The data show that the relative aggregate levels in AZD0292 ranged from 3.9% to 18.0%, and in MEDI3902, the aggregate levels ranged from 7.0% to 22.2% (Figure 9A and Figure 9B). However, clones expressing AZD0292 reported 3% fewer aggregates than those expressing MEDI3902. This percentage difference in aggregate level is greater than the analytical method error (0.1% area difference) and is therefore a significant difference. Therefore, clones expressing AZD0292 reported significantly fewer aggregates than those expressing MEDI3902.The observed level of aggregation did not correlate with expression titer, confluence, viable cell density, or cell viability. These data indicate... Petition 870250102008, dated 07 / 11 / 2025, pp. 114 / 142 106 / 106 surprisingly, the N3Y mutation in AZD0292 reduces aggregate levels compared to MEDI3902.
[0284] The full disclosures of all patents, patent applications including provisional patent applications, publications including patent publications and non-patented publications and electronically available material (including, for example, nucleotide sequence submissions in, for example, GenBank and RefSeq, and amino acid sequence submissions in, for example, SwissProt, PIR, PRF, PDB and translations of annotated coding regions in GenBank and RefSeq) cited herein are incorporated by reference. The detailed description and examples above are provided for clarity of understanding only. No unnecessary limitations should be understood from them. The invention is not limited to the exact details shown and described, as variations obvious to one skilled in the art will be included in the invention defined by the claims. Petition 870250102008, dated 07 / 11 / 2025, pp. 115 / 142
Claims
1 / 10 CLAIMS 1. A bispecific antibody that binds specifically to the PcrV protein and the Psl exopolysaccharide of Pseudomonas aeruginosa, the antibody being CHARACTERIZED by comprising a modified IgG Fc region, wherein the modified IgG Fc region comprises amino acid substitutions at two or more of the positions 432 to 437, numbered according to the Kabat EU numbering index, relative to a wild-type IgG Fc region; wherein (i) positions 432 and 437 are each substituted for cysteine; (ii) position 433 is histidine or is substituted for arginine, proline, threonine, lysine, serine, alanine, methionine or asparagine; (iii) position 434 is asparagine or is replaced by arginine, tryptophan, histidine, phenylalanine, tyrosine, serine, methionine or threonine; (iv) position 435 is histidine; and (v) position 436 is tyrosine or phenylalanine or is replaced by leucine, arginine, isoleucine, lysine, methionine, valine, histidine, serine or threonine;and with the antibody having an increased half-life compared to the half-life of a corresponding antibody with the wild-type Fc region.
2. Bispecific antibody, according to claim 1, CHARACTERIZED in that the modified IgG Fc region is a modified IgG1 Fc region.
3. Bispecific antibody, according to claim 1 or 2, CHARACTERIZED in that the modified IgG Fc region is a modified human IgG Fc region.
4. Bispecific antibody, according to any one of claims 1 to 3, the bispecific antibody being CHARACTERIZED by exhibiting less aggregation in solution than an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:
20.
5. Bispecific antibody, according to any one of claims 1 to 4, the bispecific antibody being CHARACTERIZED by promoting the opsonophagocytic killing activity of P. aeruginosa, wherein, optionally, the bispecific antibody mediates similar in vitro opsonophagocytic killing activity of P. aeruginosa as an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:
20.
6. Bispecific antibody, according to any one of claims 1 to 5, CHARACTERIZED by further comprising an amino acid insertion after position 437, and optionally the amino acid insertion is glutamic acid.
7. Bispecific antibody, according to any one of claims 1 to 6, CHARACTERIZED in that the binding affinity of the bispecific antibody for FcRn at pH 6.0 is greater than the binding affinity for FcRn of a corresponding antibody with the Fc region of wild-type human IgG1 at pH 6.
8. Bispecific antibody, according to any one of claims 1 to 7, CHARACTERIZED in that the binding affinity of the bispecific antibody for FcRn at pH 7.4 is greater than the binding affinity for FcRn of a corresponding antibody with the Fc region of wild-type human IgG1 at pH 7.
4.
9. Bispecific antibody, according to any one of claims 1 to 8, CHARACTERIZED in that the modified human IgG1 Fc region exhibits increased pH dependence in binding affinity for FcRn compared with a corresponding antibody with the wild-type human IgG1 Fc region.
10. Bispecific antibody, according to any one of claims 1 to 9, CHARACTERIZED in that the Fc region of modified human IgG1 has amino acid substitutions at three of the positions 432, 433, 434, 435, 436 and 437. Petition 870250102008, dated 07 / 11 / 2025, p. 117 / 142 3 / 10 11. Bispecific antibody, according to any one of claims 1 to 9, CHARACTERIZED in that the Fc region of modified human IgG1 has amino acid substitutions at four of the positions 432, 433, 434, 435, 436 and 437.
12. Bispecific antibody, according to any one of claims 1 to 9, CHARACTERIZED in that the Fc region of modified human IgG1 has amino acid substitutions at five of the positions 432, 433, 434, 435, 436 and 437.
13. Bispecific antibody, according to any one of claims 1 to 9, CHARACTERIZED in that the Fc region of modified human IgG1 has amino acid substitutions at six of the positions 432, 433, 434, 435, 436 and 437.
14. Bispecific antibody, according to any one of claims 1 to 9, CHARACTERIZED by the modified human IgG1 Fc region comprising the amino acid sequence of SEQ ID NO:44 and the amino acid sequence of SEQ ID NO:
33.
15. Bispecific antibody, according to any one of claims 1 to 14, the bispecific antibody being CHARACTERIZED in not being a HexaBody.
16. Bispecific antibody, according to any one of claims 1 to 15, the bispecific antibody being CHARACTERIZED by competitively inhibiting the binding to PcrV of an antibody comprising a variable heavy chain (VH) region comprising the amino acid sequence of SEQ ID NO:13 and a variable light chain (VL) region comprising the amino acid sequence of SEQ ID NO:
14.
17. Bispecific antibody, according to any one of claims 1 to 16, the bispecific antibody being CHARACTERIZED by binding to the same PcrV epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:13 and a VL comprising the amino acid sequence of SEQ ID NO:
14.
18. Bispecific antibody, according to any of the claims 1 Petition 870250102008, dated 11 / 07 / 2025, pp. 118 / 142 4 / 10 to 17, the bispecific antibody being CHARACTERIZED by comprising an antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa and comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:1, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:5 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
6.
19. Bispecific antibody, according to claim 18, CHARACTERIZED by the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa comprising a VH comprising the amino acid sequence of SEQ ID NO:13 and / or a VL comprising the amino acid sequence of SEQ ID NO:
14.
20. Bispecific antibody, according to claim 18 or claim 19, CHARACTERIZED by the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa comprising a variable heavy chain region and a variable light chain region in separate polypeptides.
21. Bispecific antibody, according to any one of claims 1 to 20, the bispecific antibody being CHARACTERIZED by competitively inhibiting the binding to Psl of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:
16.
22. Bispecific antibody, according to any one of claims 1 to 21, the bispecific antibody being CHARACTERIZED by binding to the same Psl epitope as an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and a VL comprising the amino acid sequence of SEQ ID NO:
16. Petition 870250102008, dated 11 / 07 / 2025, p. 119 / 142 5 / 10 23. Bispecific antibody, according to any one of claims 1 to 22, the antibody being CHARACTERIZED by comprising an antigen-binding domain that binds to the Pseudomonas aeruginosa exopolysaccharide Psl and comprising a variable heavy chain region VH-CDR1 comprising the amino acid sequence of SEQ ID NO:7, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:8, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:9, a variable light chain region VLCDR1 comprising the amino acid sequence of SEQ ID NO:10, a VLCDR2 comprising the amino acid sequence of SEQ ID NO:11 and a VLCDR3 comprising the amino acid sequence of SEQ ID NO:
12.
24. Bispecific antibody, according to claim 23, CHARACTERIZED by the antigen-binding domain that binds to the Pseudomonas aeruginosa exopolysaccharide Psl comprising a VH comprising the amino acid sequence of SEQ ID NO:15 and / or a VL comprising the amino acid sequence of SEQ ID NO:
16.
25. Bispecific antibody, according to claim 23 or 24, CHARACTERIZED by the antigen-binding domain binding to the Pseudomonas aeruginosa Psl exopolysaccharide comprising a VH and a VL in the same polypeptide.
26. Bispecific antibody, according to any one of claims 23 to 25, CHARACTERIZED by the antigen-binding domain that binds to the Pseudomonas aeruginosa exopolysaccharide Psl comprising a linker between VH and VL, optionally the linker comprising the amino acid sequence of SEQ ID NO:
18.
27. Bispecific antibody, according to any one of claims 23 to 26, CHARACTERIZED by the antigen-binding domain binding to the Pseudomonas aeruginosa Psl exopolysaccharide comprising an scFv. Petition 870250102008, dated 07 / 11 / 2025, p. 120 / 142 6 / 10 28. Bispecific antibody, according to claim 27, CHARACTERIZED in that scFv comprises a ligand, optionally the ligand comprising the amino acid sequence of SEQ ID NO:
18.
29. Bispecific antibody, according to claim 27 or claim 28, CHARACTERIZED in that scFv is in the VH-ligand-VL orientation.
30. Bispecific antibody, according to any one of claims 27 to 29, CHARACTERIZED by scFv comprising the amino acid sequence of SEQ ID NO:
17.
31. Bispecific antibody, according to any one of claims 27 to 30, CHARACTERIZED in that scFv is in the same polypeptide chain as VH of the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa.
32. Bispecific antibody, according to any one of claims 27 to 31, CHARACTERIZED in that scFv is C-terminal to VH of the antigen-binding domain that binds to the PcrV protein of Pseudomonas aeruginosa.
33. Bispecific antibody, according to any one of claims 1 to 32, the bispecific antibody being CHARACTERIZED by comprising (i) a heavy chain of the formula VH-CH1-H1-L1-S-L2-H2-CH2-CH3, wherein VH is a variable heavy chain domain of PcrV anti-Pseudomonas aeruginosa; CH1 is a constant region domain of heavy chain 1; H1 is a first hinge region fragment of heavy chain; L1 is a first ligand; S is an scFv molecule of Psl anti-Pseudomonas aeruginosa; L2 is a second ligand; H2 is a second hinge region fragment of heavy chain; CH2 is a constant region domain of heavy chain 2; and CH3 is a constant region domain of heavy chain 3; and (ii) a VL-CL light chain, wherein VL is a variable domain of anti-Pseudomonas aeruginosa PcrV light chain, and CL is a kappa constant region of antibody light chain or a lambda constant region of Petition 870250102008, dated 07 / 11 / 2025, page 1.121 / 142 7 / 10 light chain antibody.
34. Bispecific antibody, according to claim 33, CHARACTERIZED by CH1 comprising the amino acid sequence of SEQ ID NO:
21.
35. Bispecific antibody, according to claim 33 or claim 34, CHARACTERIZED by H1 comprising the amino acid sequence of SEQ ID NO:
22.
36. Bispecific antibody, according to any one of claims 33 to 35, CHARACTERIZED by L1 comprising the amino acid sequence of SEQ ID NO:
28.
37. Bispecific antibody, according to any one of claims 33 to 36, CHARACTERIZED by L2 comprising the amino acid sequence of SEQ ID NO:
28.
38. Bispecific antibody, according to any one of claims 33 to 37, CHARACTERIZED by H2 comprising the amino acid sequence of SEQ ID NO:
23.
39. Bispecific antibody, according to any one of claims 33 to 38, CHARACTERIZED by CH2-CH3 comprising the amino acid sequence of SEQ ID NO:
30.
40. Bispecific antibody, according to any one of claims 33 to 39, CHARACTERIZED in that CL is a constant kappa region of the antibody light chain.
41. Bispecific antibody, according to any one of claims 33 to 40, CHARACTERIZED by CL comprising the amino acid sequence of SEQ ID NO:
24.
42. Bispecific antibody, according to any one of claims 1 to 41, CHARACTERIZED by comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:31 and / or a light chain comprising the amino acid sequence of SEQ ID NO:
20.
43. Isolated polynucleotide CHARACTERIZED by comprising a nucleic acid molecule encoding the heavy chain of the bispecific antibody as defined in any one of claims 1 to 42.
44. Isolated polynucleotide, according to claim 43, CHARACTERIZED by further comprising a nucleic acid molecule encoding the bispecific antibody light chain as defined in any one of claims 1 to 42.
45. Vector CHARACTERIZED by comprising the polynucleotide as defined in claim 43 or 44.
46. Host cell CHARACTERIZED by comprising (i) the polynucleotide as defined in claim 43 or 44, or (ii) the vector as defined in claim 45.
47. Method for producing a bispecific antibody, the method being characterized by comprising cultivating the host cell as defined in claim 46, and optionally isolating the bispecific antibody.
48. Bispecific antibody CHARACTERIZED by being produced by the method as defined in claim 47.
49. Composition CHARACTERIZED by comprising the bispecific antibody as defined in any one of claims 1 to 42 or 48, and a pharmaceutically acceptable carrier.
50. A method for treating or preventing a Pseudomonas infection in an individual in need thereof, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual. Petition 870250102008, dated 07 / 11 / 2025, pp. 123 / 142 9 / 10 51. Method according to claim 50, CHARACTERIZED in that the infection is a lung infection, a respiratory tract infection, pneumonia, bacteremia, a bone infection, a joint infection, a skin infection, a burn infection, a wound infection or any combination thereof.
52. A method for treating bronchiectasis in an individual in need thereof, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
53. A method for improving forced expiratory volume (FEVi) with a pre-bronchodilator in an individual with bronchiectasis, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
54. A method for reducing the Pseudomonas aeruginosa load in an individual with bronchiectasis, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
55. A method for reducing bronchiectasis exacerbations in an individual in need thereof, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
56. Method for reducing the need for intravenous antibiotics in an individual with bronchiectasis, the method being CHARACTERIZED by comprising Petition 870250102008, dated 07 / 11 / 2025, pp. 124 / 142 10 / 10 administering the bispecific antibody as defined in any of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
57. A method for stabilizing lung function in an individual with bronchiectasis, the method being characterized by comprising administering the bispecific antibody as defined in any one of claims 1 to 42 or 48, or the composition as defined in claim 49, to the individual.
58. Method, according to any one of claims 52 to 57, CHARACTERIZED in that the bronchiectasis is non-cystic fibrosis bronchiectasis.
59. Method, according to any one of claims 50 to 58, CHARACTERIZED by further comprising administering an antibiotic.
60. Method, according to any one of claims 50 to 59, CHARACTERIZED in that the individual is colonized with Pseudomonas aeruginosa, and optionally the respiratory tract of the individual is colonized with Pseudomonas aeruginosa.
61. Use of the bispecific antibody as defined in any one of claims 1 to 42 or 48, or of the composition as defined in claim 49, CHARACTERIZED by being intended for the preparation of a medicament for use in the method as defined in any one of claims 50 to 60.
62. Bispecific antibody, according to any one of claims 1 to 42 or 48, or composition, according to claim 49, CHARACTERIZED by being intended for use in the method as defined in any one of claims 50 to 60. Petition 870250102008, dated 07 / 11 / 2025, pp. 125 / 142
